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ABSTRACT
Neurons are the primary research target in the exploration and development of
novel smoking cessation pharmacotherapies over the years. These research
efforts have led to the discovery and development of three FDA-approved smoking
cessation aids – nicotine replacement therapy, varenicline, and bupropion, each
of which have quantifiable success as smoking cessation aids. However, relapse
is still very common and smoking cessation is successful in less than 5% of quit
attempts, making paramount the development of novel therapeutics. One
untapped therapeutic target are glia, particularly, astrocytes and microglia, which
are active participants in the neuroplastic events underlying drug addiction.
First, we examined microglial changes in the striatum – a mesolimbic brain
region implicated in both the rewarding effects of drugs and the affective
disruptions occurring during drug withdrawal. We show that chronic nicotine and
withdrawal induce microglial activation accompanied with distinct expression of
pro-inflammatory cytokines in the nucleus accumbens.

Nicotine withdrawal-

related pro-inflammatory effects accompany activation of microglia-related
NADPH Oxidase 2 (Nox2) and induction of reactive oxygen species (ROS). Both
cellular correlates of inflammation and increased anxiety-like behaviors occurring
during nicotine withdrawal are absent following microglial depletion with colony
stimulating factor 1 receptor inhibitor, PLX5622.
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Based on these findings, we extended our study to capture tissue-level
transcriptome-wide responses in the nucleus accumbens during chronic nicotine
and withdrawal (24 h and 48 h). We show temporally-dependent activation of
distinct gene programs in the nucleus accumbens during nicotine withdrawal.
Differential gene expression analysis suggests that chronic nicotine treatment
activates subset of genes that are neuroprotective while withdrawal from nicotine
provokes neuroinflammation and oxidative stress-related transcriptional programs
in the nucleus accumbens
To have a finer resolution that aid better characterization of transcriptomic
changes, we performed cell type-specific RNA sequencing and evaluated
astrocyte- and microglia-specific transcriptome changes during nicotine treatment
and 48 h withdrawal. We show that gene programs associated with
neuroinflammation were suppressed in microglia following chronic nicotine
treatment while nicotine withdrawal triggers microglial pro-inflammatory networks.
Further, whole transcriptome data suggest astrocytes assume a reactive
phenotype during nicotine withdrawal.
Taken together, this work provides the first evidence of microglia involvement
in nicotine dependence. In addition, our transcriptomic studies offer a less complex
insight into the role of nucleus accumbal glia in nicotine dependency, pioneering
future exploration of glia modulators as potential therapeutic targets for the
development of smoking cessation therapeutics.
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CHAPTER 1
GENERAL INTRODUCTION

________________________________
1

Adewale Adeluyi, Jill R. Turner. To be submitted to Nicotine and Tobacco
Research.
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1.1

GENERAL OVERVIEW OF NICOTINE DEPENDENCE

Tobacco smoking is the principal cause of preventable disease and premature
death in the world. Globally, over 5 million premature deaths are attributable to
tobacco smoking every single year, and nearly one-tenth – about 480,000, of these
deaths occur in the United States (Changeux 2010, Reitsma et al 2017). Despite
decreased smoking prevalence in the United States over the last decade, the
disease burden attributable to tobacco smoking continues to rise. This is due in
part to population growth, but also the high failure rate in quit attempts made by
current smokers (Ng et al 2014).
Currently, over 42 million Americans still smoke, and nearly 80% of these
smokers have made serious attempts to quit without success (Benowitz 2010).
While quitting smoking significantly reduces the risk of smoking-related disease
and death, successful smoking cessation remains a major challenge in the United
States with only 3% success rate in quit attempts each year (Benowitz 2010,
Changeux 2010). Today, it has become clearer that effects of nicotine and its
withdrawal (during smoking cessation) on neural circuits relevant in nicotine
dependence are more complex than initially thought. Therefore, in this chapter, I
will discuss the molecular effects of nicotine, highlighting some of these effects in
a well-defined neurocircuitry of addiction. Further, I will review the symptomology
of nicotine withdrawal and the potential role of non-neuronal cell types in nicotine
dependence.
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1.2

NEUROBIOLOGY OF NICOTINE DEPENDENCE

Nicotine and Neuronal Nicotinic Acetylcholine Receptors (nAChRs) – Acute
Effects
Nicotine is the major psychoactive component in tobacco that drives the
neurobiological effects underlying the sustainment and reinforcement of tobacco
smoking (Balfour 2008, Benowitz 2010, Grunberg 2007). Smoke particles
containing nicotine are inhaled into the lungs, where about 90% of nicotine present
in the inhaled smoke is immediately absorbed into the pulmonary venous
circulation (Jiloha 2014). Following absorption, it takes seven seconds for nicotine
to reach the brain (Jiloha 2010), where it binds and activates nicotinic acetylcholine
receptors (nAChRs). These receptors are ionotropic and are comprised of 5
subunits. There are 12 nAChR subunits expressed in the mammalian brain,
including α2 - α10 and β2 - β4. Neuronal nAChRs can exist as either homomeric
nAChR subtypes, in which all subunits are the same (i.e., α7 nAChRs), or as
heteromeric nAChR subtypes, which are a mix of different subunits (i.e., α4β2
nAChRs). This varying subunit composition influences the pharmacological
features of nAChRs, and ultimately their responses to nicotine stimulation
(D'Souza & Markou 2011, Govind et al 2009). For example, evidences from
preclinical studies have indicated that α4-, α5-, α6-, α7-, and β2-containing
nAChRs mediate the reinforcing and behavioral effects of nicotine (Fowler et al
2008).
Activation of nAChRs opens the cationic channel, allowing passage of
potassium, sodium and calcium ions. Because nAChRs are preferentially located
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at the presynaptic terminal, their effects are primarily modulatory and result in the
release of nearly every major neurotransmitter (Benowitz 2010, Markou 2008).
This results in a diverse array of effects. For example, dopamine, one of the
several neurotransmitters released following nAChR activation, is highly linked to
nicotine’s reinforcing and rewarding properties (Jiloha 2010, Volkow & Li 2004).
Other neurotransmitters modulated by nAChRs include γ-aminobutyric acid
(GABA), β-endorphin, glutamate, serotonin, acetylcholine, and norepinephrine
(Jiloha 2010). The release of GABA or β-endorphins results in attenuation of
anxiety and tension (Benowitz 1999). Increased levels of glutamate enhance
learning and memory, while serotonin release is connected to mood modulation
and appetite suppression (Benowitz 1999). Both acetylcholine and norepinephrine
modulate arousal but in addition, the release of acetylcholine enhances cognition
while increased norepinephrine levels suppress appetite (Benowitz 1999).
nAChRs’ propensity to promote release of myriad neurotransmitters following their
activation provides a functional basis for nicotine’s modulation of various behaviors
(Benowitz 2008a).

Nicotine and Neuronal Nicotinic Acetylcholine Receptors (nAChRs) –
Chronic Effects
Chronic nicotine exposure results in numerous neuroadaptations within the brain.
One prime example is the canonical subtype-specific upregulation of nAChRs
(Buisson & Bertrand 2001, Changeux et al 1984). The term “upregulation”
describes the persistent increase in nAChR radio-ligand binding sites in the brain
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following long-term nicotine exposure. It is noteworthy that the receptor binding
affinity of nicotine depends on nAChR subunit composition, which ultimately
influence Ca2+ permeability as well as the tendency and extent of nicotine-induced
upregulation. For example, a large percentage (~90%) of high affinity nicotine
binding sites in the brain are made up of α4 and β2 subunits (Whiting & Lindstrom
1988). In addition, studies have shown that incorporation of β4 into α6- or α3containing nAChRs leads to a remarkable degree of upregulation by nicotine, while
the presence of α5- or α3-subunits in b2-contatining nAChRs seems to block
upregulation by nicotine (Govind et al 2009). Several molecular mechanisms have
been proposed for nicotine-induced upregulation of nAChR subtypes. First, unlike
acetylcholine, nicotine is not a substrate for acetylcholine esterase hydrolytic
degradation. As a result, nicotine’s presence and activity are prolonged, which
consequently leads to nAChRs desensitization. The suggested neuronal adaptive
response to long-term desensitization of nAChRs is upregulation (Picciotto et al
2008, Wonnacott 1990). In contrast, another study demonstrated that nicotineinduced nAChR upregulation is an intrinsic attribute of the nAChR protein rather
than the suggested adaptive response of neurons expressing these receptors
(Peng et al 1994). In support, they showed that upregulation results from
decreased surface nAChR turnover, which is associated with nicotine-induced
changes in nAChR conformation (Peng et al 1994). Another proposed mechanism
for nicotine-induced upregulation is nicotine’s blockade of nAChR degradation
through modulation of proteasomal activity (Ficklin et al 2005, Rezvani et al 2007).
Other processes that may contribute to nAChR upregulation include increased
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nAChR trafficking to the cell surface (Darsow et al 2005) and increased nAChR
subunit maturation and assemblage (Harkness & Millar 2002, Sallette et al 2005).
Another critical aspect of nicotine-induced neuroadaptation is that upregulation of
nAChRs occur in a subtype-specific manner, and each of these receptor subtypes
are differentially expressed across brain regions. These regional dissimilarities in
nAChR subtype expression and upregulation following chronic nicotine use may
influence nicotine-induced neuroadaptation in various neural circuitry (De Biasi &
Dani 2011). Evidence of such diversity in nAChR subtype expression and
upregulation have been shown in the mesolimbic dopamine reward circuit. For
example, striatal dopaminergic neurons primarily express five nAChR subtypes –
α4α5β2, α4α6β2β3, α4β2, α6β2β3, α6β2; however, the expression density of the
α4* subtypes is higher compared to the α6* subtypes across the striatum (Grady
et al 2007). α4β2 nAChR is one of the most abundant and widely distributed
nAChR subtypes in the brain. It is well expressed by both dopaminergic and nondopaminergic neurons in the striatum, but a subpopulation also containing α5
(α4α5β2 subtype) is only expressed on the striatal dopaminergic terminals (Zoli et
al 2002). Amongst many other nAChR subtypes, α4β2 nAChRs are the most
implicated in nicotine-induced neuroadaptation and nicotine dependency
(Benowitz 2008b). For example, evidence from previous studies examining
functional upregulation of nAChR, a direct and important nicotine-induced
neuroadaptation, have demonstrated that α4β2 subtype is the most upregulated in
the brain compared to other nAChR subtypes (Buisson & Bertrand 2002). Another
study also reported that chronic nicotine administration selectively increases the
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expression of α4β2 nAChR on dopaminergic terminals in the striatum, and more
importantly, this receptor remains functional in contrast to the general idea that
upregulated receptors are desensitized (Xiao et al 2009). Further studies also
implicated selective upregulation of α4β2 nAChR in presynaptic modulation of
dopamine release in the striatum (Sharples et al 2000), even though, another study
showed that α6β2β3 nAChR can partly contribute to this nAChR-related function
in the striatum (Cao et al 2005). However, it is noteworthy to mention that there is
ambiguity in findings related to nicotine-induced upregulation of α6β2 receptors.
While a study that utilized mammalian cell lines showed that co-expression of β3subunits increase in α6β2 and α6β4 receptor levels (Tumkosit et al 2006), another
study in brain tissue showed that striatal α6-containing receptors without β3 are
downregulated by nicotine and those containing β3 are unaltered.

1.3

MAJOR NEURAL PATHWAYS INVOLVED IN NICOTINE DEPENDENCE

Following

nAChR

activation

in

the

brain,

nicotine

engages

multiple

neurotransmitter systems, usurping their neural elements to precipitate its effects.
One of these neurotransmitter systems is the brain’s dopaminergic system, which
is the primary neural framework mediating the reinforcing and rewarding effects of
nicotine. Other key neurotransmitter systems are the major excitatory and
inhibitory neurotransmitters in the brain, namely glutamate and GABA,
respectively. Both neurotransmitters can modulate nicotine’s reinforcing and
rewarding effect by enhancing (glutamate) or inhibiting (GABA) dopamine release
in the mesocorticolimbic circuits. Excitatory and inhibitory control of nicotine-
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induced dopamine effects is possible because of complex interactions existing
between mesocorticolimbic dopaminergic neurons and the glutamatergic inputs
from the cortical and limbic nuclei, and GABAergic inputs from the local
interneurons as well as interneurons from distant nuclei (D'Souza & Markou 2013,
Yager et al 2015). Studies investigating how these interactions impact nicotine
dependence have shown that inhibition of glutamatergic neurotransmission or
stimulation of GABAergic neurotransmission attenuates nicotine intake and
nicotine-seeking behavior in rodents (D'Souza & Markou 2013).

Mesocorticolimbic pathway
The mesocorticolimbic pathway, also known as the reward pathway, is the critical
neural pathway for reinforcing rewarding behaviors, including those behaviors
underlying drug addiction. All drugs of abuse including nicotine are believed to
enhance the effect of dopaminergic function in the mesocorticolimbic pathway,
particularly, at the dopaminergic nerve terminals in the nucleus accumbens (NAc)
– a key neural substrate of motivation and reward (D'Souza & Markou 2011, Dani
& De Biasi 2013, Hyman et al 2006, Volkow & Li 2004). Apart from the NAc, other
major brain structures in the dopaminergic pathway includes ventral tegmental
area (VTA), prefrontal cortex (PFC), substantia nigra (SNr), and caudate-putamen
(CPu). Although dopaminergic neurons originate from both SNr and VTA, these
structures project to different brain regions. Dopaminergic axons from the SNr
project to the caudate putamen in the nigrostriatal pathway, while the axons of
dopaminergic neurons in the VTA project primarily to the NAc and PFC in the
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mesocorticolimbic circuit (Figure 1). In drug addiction, the role of dopaminergic
axon projection from SNr to its targets is not really well-defined (Dani & De Biasi
2013), even though it is a well-described motor circuit. However, VTA
dopaminergic projections to the NAc have been identified as the principal neural

Figure 1.1: Simplified mesocorticolimbic and nigrostriatal pathways

framework shaping reward-related behaviors. In fact, in the context of drug
addiction, this pathway is the most crucial neural substrate for acute rewarding
effects of all drugs of abuse, regardless of their dissimilar mechanism of action
(Markou 2008, Volkow & Li 2004, Volkow & Morales 2015). Nicotine’s activation of
the VTA-NAc pathway can occur either directly via stimulation of nAChRs on VTANAc dopaminergic terminals in the VTA or indirectly through stimulation of nAChRs
on glutamatergic nerve terminals innervating dopaminergic neurons in the VTA
(D'Souza & Markou 2011). Regardless, both activation pathways lead to dopamine
release in the NAc.
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Striatum Neuroanatomy
The striatum is a critical component of the mesocorticolimbic system, and it is a
heterogeneous structure with two distinct subregions – the dorsal striatum (mainly
the CPu) and the ventral striatum (mainly the NAc). These striatal subregions are
the main input structures in the mesocorticolimbic pathway, functioning as hubs
coordinating various neuronal activities. Major inputs received by these subregions
includes the dopaminergic inputs from VTA and SNr, and the glutamatergic
projections from the PFC. Both inputs physically interact at different sites on the
dendritic spines of striatal GABAergic medium spiny neurons (MSN), which
account for ~95% of the striatal neuronal population (Yager et al 2015). This
complex interaction controls MSN activity within the striatum (Yager et al 2015).
Striatal MSNs relay information to neighboring structures such as SNr via the direct
pathway (dMSNs) and to the subthalamic nuclei (STN) via the indirect pathway
(iMSNs). While these striatal output pathways are found in both the CPu and NAc,
their target structures are different. In the NAc, the iMSNs, which primarily express
dopamine D2 receptors, specifically project to the ventral pallidum (VP), and the
dMSNs, which generally express dopamine D1 receptors, project mainly to the
VTA and SNr. In contrast, iMSNs in the CPu project largely to the globus pallidus
external (GPe) and STN, while its dMSNs extend particularly to the globus pallidus
internal (GPi) and SNr. Of note, these striatal output pathways are not absolutely
separated as there can still be overlapping projections such as the extension of
dMSNs axon collaterals to the GPe/VP (Fujiyama et al 2011). In drug addiction,
the CPu and the NAc have differing functional roles, even though in a simplistic
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view they both receive similar neuronal inputs. For instance, as drug addiction
progresses from occasional recreational use to compulsive use, drug-seeking
behavior is thought to switch from reward-driven to habit-driven – drug-seeking
behaviors that are controlled by NAc and CPu respectively (Clarke & Adermark
2015). This differential role is supported by several studies such as that which
previously demonstrated dissimilar dopamine signaling in the CPu and NAc
following chronic nicotine use (Zhang et al 2009). Overall, these differences in the
neuroanatomical organization of caudate-putamen and nucleus accumbal
afferents and efferents contribute to their differential roles in motivation and motor
function.

1.4

ROLE OF WITHDRAWAL SYMPTOMS IN NICOTINE DEPENDENCE

Nicotine withdrawal symptoms manifest a few hours after discontinuation of
nicotine use, and the collection of these negative symptoms during abstinence
from nicotine is the major determinant preventing smokers from successful quitting
(McLaughlin et al 2015). Symptoms of nicotine withdrawal encompass affective,
cognitive, and somatic domains. Affective symptoms include anxiety, depression,
irritability, anhedonia, hyperalgesia, and dysphoria, while memory impairment and
difficulty concentrating are cognitive manifestations (McLaughlin et al 2015).
Together, the biological basis of nicotine addiction can be regarded as a mix of
positive reinforcement, such as mood enhancement, and avoidance of negative
effects associated with nicotine withdrawal (Benowitz 2010, Cosci 2011, Markou
2008).
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Anxiety-Related Withdrawal Phenotypes
Affective nicotine withdrawal symptoms are critical determinants of smoking
motivation (Leventhal et al 2013) and individuals who quit smoking often
experience symptoms of anxiety. A randomized placebo-controlled clinical trial has
shown that anxiety is a discrete, quantifiable affective manifestation of nicotine
withdrawal, which directly impacts relapse to smoking (Piper et al 2011). To
advance the current understanding of anxiety-like behaviors during withdrawal
from nicotine, better insight into the neurocircuitry and neuroadaptations
associated with withdrawal-induced anxiety is critical.
There is mounting evidence implicating the mesolimbic dopamine signaling
in the neurobiology of mood and anxiety (Russo & Nestler 2013). One of the critical
neural substrates of anxiety-like behaviors in the mesolimbic pathway is the
nucleus accumbens. The nucleus accumbens plays an important role in anxiety
disorders (Levita et al 2012, Russo & Nestler 2013) and nicotine withdrawal-related
anxiety (Morud et al 2018, Torres et al 2015). Besides the nucleus accumbens,
studies have also demonstrated the role of ventral hippocampus (Fisher et al 2017)
and medial habenula (McLaughlin et al 2015, Pang et al 2016) in nicotine
withdrawal-related anxiety. This indicates that withdrawal-related anxiety may be
a function of molecular disruptions or neuroadaptive changes in multiple
neuroanatomical structures or neurocircuitry. Withdrawal from nicotine during
smoking cessation alters nAChR number or function in widely distributed neural
circuits such as the mesocorticolimbic circuitry, and these changes have been
shown to coincide with anxiety (Grady et al 2007, Yohn et al 2014). Studies have

12

also shown that withdrawal-induced anxiety can be influenced by the subunit
composition of nAChRs. For instance, α6- and β2-containing nAChR subunits are
required for increased anxiety during nicotine withdrawal (Jackson et al 2008,
Jackson et al 2009), while α5 and α7 may not be necessary (Jackson et al 2008).
Generally, quantification of anxiety and other affective symptoms in rodents
are relatively subtler than somatic signs, which are the most often evaluated
withdrawal symptoms in rodent models. One of the well-validated behavioral
paradigms commonly used in assessing anxiety-like behavior in chronic nicotine
studies is the novelty-induced hypophagia (NIH), which is very sensitive to acute
treatment with anxiolytic drugs. The NIH test is a hyponeophagia-based paradigm
that quantifies anxiety based on animals’ latency to feed in a novel environment
(Dulawa & Hen 2005, Fisher et al 2017). Open field (Cohen et al 2009) and marbleburying (Turner et al 2014, Turner et al 2013b) tests are also frequently used in
evaluating anxiogenic behavior in mice. Both behavioral paradigms, similar to NIH,
are well-validated models with high predictive validity for anxiolytics and
antidepressants.

Cognition-Related WD Phenotypes
Cognition is a brain-related function that is negatively impacted by nicotine
withdrawal. Impaired neurocognitive control during nicotine withdrawal often
manifest as inability to change nicotine-seeking and -taking responses that are
provoked by stimuli related to previous nicotine’s rewarding effects. This symptom
is basically characterized with attention deficits and memory impairment, and
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together with affective nicotine withdrawal symptoms, are thought to predict
relapse (Ashare et al 2014). Previous studies in mice and humans have shown
that re-exposure to nicotine can reverse nicotine withdrawal-related cognitive
deficits (Davis et al 2005, Ernst et al 2001, Patterson et al 2009, Portugal & Gould
2007).
An important neural substrate of cognitive control processes is the
frontostriatal circuits, which include discrete regions of the prefrontal cortex and
the striatum. The frontostriatal circuits are critical neural pathways for executive
functions, which include adaptation to changes, decision making, working memory,
planning and organization. These cognitive functions are normally disrupted during
nicotine withdrawal (Parikh et al 2016). However, while the neural mechanism
altered during nicotine withdrawal is still not completely understood, changes in
nAChR numbers and function may contribute to the disruption and impairment of
cognitive control processes during nicotine withdrawal. For example, studies have
indicated that β2-containing nAChRs, including α4β2 receptors, mediate nicotine
withdrawal-related deficits in contextual fear conditioning (Gould et al 2012,
Portugal et al 2008), which is a form of associative learning. Evaluation of
associative learning can be performed in rodents by utilizing contextual and cued
fear conditioning test, which are behavioral models that assess the ability of a mice
to learn and recall an association between environmental cues (context such as a
location or stimulus such as a tone) and aversive experiences (aversive stimuli
such as an electric shock) (Ashare et al 2014). Another relevant behavioral
paradigm of cognition is the novel object recognition test. This test is frequently

14

utilized in evaluating memory-related cognitive deficits. It assesses rodents based
on their tendency to spend more time exploring a novel object rather than a familiar
one. One more cognitive control process that may be impaired during nicotine
withdrawal is attention. Attention-related cognitive deficits are evaluated in rodents
by performing operant signal detection task (Ashare et al 2014).

1.5

NOVEL TARGETS FOR SMOKING CESSATION: NON-NEURONAL

CELLS IN NICOTINE DEPENDENCE
Over the years, exploration of neuronal targets has been the primary research
focus of nicotine dependency; however, it is becoming evident that non-neuronal
cell-types such as astrocytes and microglia, are actively involved in the functional
organization of the brain (Allen & Barres 2009, Cerbai et al 2012). Both neuronal
and non-neuronal cell-types constantly interact in their local microenvironment to
maintain the integrity of brain structures (Allen & Barres 2009). However, impaired
interplay amongst these brain cell-types as a consequence of chronic exposure to
nicotine may be a major determinant underlying high relapse rates among
smokers.

Astrocytes
Astrocytes are the most abundant glial cells in the mammalian brain. They are
morphologically complex cells with numerous processes, which are typically
bushy. However, with their finest branching processes, they physically interact with
blood vessels, other glial cells, and synapses (main elements are presynaptic and

15

postsynaptic terminals) in a structure known as the tripartite synapses. It is
considered that finely branching processes from a single astrocyte physically
interact with several hundreds of multiple neuronal dendrites and wraps over
100,000 synapses in the hippocampus or cortex (Sofroniew & Vinters 2010).
Similar studies in the hippocampus demonstrated that ~57% of synapses are in
physical contact with astrocytes (Harada et al 2015).
Furthermore, astrocytes can exhibit regional heterogeneity with respect to
their ratio to that of neurons (astrocyte-to-neuron ratio). They exist in high density
in some neural circuits such as the cerebral cortex, where the astrocyte-to-neuron
ratio is high, and low density in some regions like the cerebellum, where the
astrocyte-to-neuron ratio is low (Khakh & Sofroniew 2015). The functional
relevance of this regional diversity is still unclear.
The role of astrocytes in the brain were once thought to be limited to
metabolic and trophic support for neurons, ionic and pH homeostasis, and the
formation and maintenance of the blood-brain barrier; however, it is now becoming
more evident that astrocytes are active participants in the modulation of neuronal
activity in the brain. Drugs of abuse such as nicotine can disrupt the interplay
between astrocyte and neuron in the brain by direct or indirect modulation. For
direct modulation, nicotine can directly bind to nAChRs on astrocytes. Studies
have demonstrated that astrocytes express α3, α4, α7, β3, β4 subunits of nAChR,
with the α7 subunit being the most predominantly expressed (Gotti & Clementi
2004). In addition, α3β4 and α4β2 nAChR expression have also been reported in
the soma and processes of astrocytes (Graham et al 2003). Several studies have
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linked astrocyte nAChRs, especially the α7-subtype, to neuroinflammatory
processes in Alzheimer’s (Teaktong et al 2003) and Parkinson’s disease (Liu et al
2015, Quik et al 2009), both neurodegenerative disorders in which nicotine use
has been reported as beneficial (Newhouse et al 2012, Villafane et al 2007).
Nicotine’s interaction with astrocyte nAChRs may further result in an increase in
the intracellular Ca2+ concentration (Sharma & Vijayaraghavan 2001) and
subsequent release of gliotransmitters. Gliotransmitters can alter synaptic activity
and function in neural circuits. For example, a study examining nicotine’s
modulation of neuron-glial interaction showed that the release of astrocyte Dserine following nicotine stimulation is necessary for nicotine’s enhancement of
synaptic transmission and long-term memory (Lopez-Hidalgo et al 2012).
However, for indirect modulation, nicotine can regulate astrocyte activity and
function by releasing neuromodulators such as dopamine. For instance, a recently
published study demonstrated that extracellular dopamine can modulate astrocyte
morphology and function (Galloway et al 2018).
One other mechanism through which astrocytes actively participate in
synaptic transmission is the clearance of small molecule neurotransmitters, such
as glutamate. Excitatory amino acid transporter (EAAT2), which is primarily
expressed on astrocytes, plays a major role in glutamate clearance – responsible
for >90% glutamate uptake (Kim et al 2011). Elevated glutamate levels in the brain
underlies many neurodegenerative and neurological disorders, and dysfunctional
EAAT2 have been linked with the initiation of a number of these brain disorders
(Kim et al 2011). Similarly, in nicotine addiction studies, rats undergoing withdrawal
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from chronic nicotine were found to have decreased EAAT2 expression
(Knackstedt et al 2009), indicating a role for this astrocyte glutamate transporter in
nicotine seeking behaviors (Spencer & Kalivas 2017). Together, astrocytes may
be active participants in the regulation of neuronal activities that are key for nicotine
dependency.

Microglia
Microglia are the resident innate immune cells in the brain and account for ~10%
of the CNS cell population in the healthy brain (Salter & Stevens 2017). In terms
of their developmental origin and functions, microglia are a unique population
among the other brain cell-types. Like peripheral myeloid cells, microglia are
derived from mesoderm lineage, and are unlike other brain cell-types, which are
derived from neuroectodermal progenitors. Recent lineage-tracing studies
provided additional characterization of microglia origin, showing that they are
derived from the yolk-sac progenitors – an embryonic origin distinct from that of
the peripheral myeloid populations (Madore et al 2017).
Microglia are highly branched, dynamic cells with relatively rapid movement
compared to other brain cell-types. These features, in addition to their fine motile
processes, allows them to constantly scan the brain parenchyma to maintain
homeostasis. Further, as CNS surveillance elements, microglia can sense and
respond accordingly to extracellular signals. Based on the signal pattern, microglia
can assume diverse morphological phenotypes that have been previously
classified into M1 microglia – the pro-inflammatory activation phenotype, or M2
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microglia

-

the

anti-inflammatory

activation

phenotype.

This

simplistic

characterization of microglia activation phenotypes is based on the presence of
particular cell surface molecules and the expression of specific sets of cytokines
(Butovsky & Weiner 2018). For example, M1 microglia were associated with
factors such as tumor necrosis factor alpha (Tnfα), interleukin-1-beta (Il1β), and
reactive oxygen species (ROS), while M2 microglia were typified by interleukin-10
(Il10) and transforming growth factor beta (TGF-β) (Butovsky & Weiner 2018, Tang
& Le 2016). However, evidence from more recent studies that re-characterize
microglial diversity (Butovsky et al 2014) have shown that the simplistic view of
microglial phenotype does not sufficiently represent the intricate physiology of
microglial cells (Ransohoff 2016). In addition to the phenotypic complexities of
microglia, they are also largely heterogeneous across diverse neural circuits and
brain regions. For example, a recent study that examined microglial phenotypes
among a group of subcortical nuclei revealed that microglia across the basal
ganglia are very diverse in terms of their density and morphology, metabolic and
activational state, and transcriptome (De Biase et al 2017). This implicates local
cues as a critical mediator of microglia phenotype across neural circuit (McCarthy
2017). Further, regional microglial heterogeneity may also reflect diverse
functional phenotypes required for the integrity of the various CNS environment in
which the microglia lives.
Microglia were once considered only as support cells in the brain (Streit
2002), but recent evidences suggest they are active players in brain function and
dysfunction (Salter & Stevens 2017). In addition to their immune functions,
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microglia are critical elements in synaptic remodeling and plasticity (Miyamoto et
al 2016, Torres et al 2016), placing them as a potential

participant in

neuroplasticity underlying drug addiction. Similar to astrocytes, nicotine and many
other drugs of abuse can directly modulate microglial morphology and function via
interaction with nAChR on microglia. However, to date, α7-nAChR is the only
nAChR subtype reportedly found on microglia. It is noteworthy to mention that most
studies, except one (Shytle et al 2004), that have reported α7-nAChR expression
on microglia were done in immortalized microglial cell lines or primary microglial
cultures (De Simone et al 2005, King et al 2017, Mencel et al 2013, Shytle et al
2004, Suzuki et al 2006), which both have their own drawbacks (Stansley et al
2012). Microglia may also be indirectly modulated by nicotine via neurotransmitter
release. Human induced pluripotent stem cells, human postmortem tissues, or
rodents may be more suitable models for investigating nicotine’s interaction with
microglia. At the present time, nicotine’s modulatory mechanism of microglial
function and how these may impact behavior are still unclear. However, a recent
study demonstrated that microglial activation and impaired neurogenesis are
associated with cognitive deficits during nicotine withdrawal (Saravia et al 2019).
While microglia may actively contribute to nicotine dependency, research studies
investigating the role of microglia in nicotine dependence is still in the early stages.

1.6

CONCLUSION

This chapter extensively covered acute and chronic effects of nicotine, as well as
the neural substrate of motivation and reward-related behaviors. We discussed
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functional upregulation of nAChRs, a nicotine-induced neuroadaptation, and
highlighted its potential role in nicotine withdrawal-related behaviors. Finally, rather
than the conventional research focus on neuronal targets, we explored the
possibilities of non-neuronal cell types as novel targets in the development of new
smoking cessation aids.

Future of pharmacotherapy development and potential role of glial targets
There are presently three FDA-approved first-line smoking cessation medications:
Nicotine Replacement Therapy (NRT), bupropion, and varenicline (Jiloha 2014,
Prochaska & Benowitz 2016). However, despite years of innovation and
advancement in the development of smoking cessation medications, a large
population of smokers attempting to quit still fail. This may be largely attributable
to the inability of current smoking cessation therapies to address some critical
aspects of nicotine dependency. For instance, all the three FDA-approved smoking
cessation medications were developed to mechanistically target neuronal
nAChRs, neglecting the possible contributions of targets on non-neuronal cells like
astrocytes and microglia.
To advance nicotine addiction research, novel studies exploring astrocytes
and microglia function in nicotine dependence should be prioritized. Long-term,
this may represent an untapped therapeutic avenue for smoking cessation.
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CHAPTER 2
MICROGLIAL MORPHOLOGY AND PROINFLAMMATORY
SIGNALING IN THE NUCLEUS ACCUMBENS DURING NICOTINE
WITHDRAWAL1

________________________________
1

Adewale Adeluyi, Lindsey Guerin, Miranda L. Fisher, Ashley Galloway, Robert
D. Cole, Sherine S. L. Chan, Michael D. Wyatt, Shannon W. Davis, Linnea R. Freeman,
Pavel I. Ortinski, Jill R. Turner. Submitted to Science Advance, 4/15/2019.
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2.1

ABSTRACT

Microglia are active participants in the pathogenesis of several neurodegenerative
diseases; however, their role in nicotine withdrawal-related anxiety, which directly
impacts relapse to smoking in humans, is unknown. This study outlines a series of
novel findings that demonstrate alteration in microglial morphology and function
underlies nicotine withdrawal-related anxiety. Here, we examined the striatum – a
key brain region implicated in reward-related processes and affective behavioral
symptoms such as anxiety. First, we show that both chronic nicotine and
withdrawal provoke microglial activation in the nucleus accumbens but not the
caudate putamen. Further, in the nucleus accumbens, nicotine withdrawal induces
proinflammatory responses, which was muted during chronic nicotine treatment.
Similarly, microglia-related NADPH oxidase 2 (Nox2) induction and aberrant
reactive oxygen species (ROS) production occurred during nicotine withdrawal,
but not during chronic nicotine treatment, in the nucleus accumbens. We utilized a
well-described antioxidant, N-acetylcysteine (NAC), and show that aberrant ROS
production significantly contributes to nicotine withdrawal-related anxiety. Further,
depletion of microglia with PLX5622 attenuates both nucleus accumbal Nox2 and
ROS, as well as nicotine withdrawal-related anxiety. More directly, our microglia
depletion studies reveal a strong link between microglial function and nicotine
withdrawal-related anxiety. Taken together, we provide the first evidence that
nicotine withdrawal alters microglial morphology and function, which underlies
nicotine

withdrawal-related

anxiety.

Long-term,
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further

investigation

into

modulators of microglial function during nicotine withdrawal represents an
untapped therapeutic avenue for smoking cessation.

2.2

INTRODUCTION

While smoking cessation significantly reduces the risk of smoking-related diseases
such as cancer, stroke, respiratory and heart diseases (Babizhayev 2014, Samet
2013), nearly 80% of smokers attempting to quit still fail (Polosa & Benowitz 2011).
Currently, tobacco smoking is the leading cause of preventable morbidity and
mortality globally (World Health Organization 2012), which underscores the need
for better therapeutics for nicotine dependence. Pharmacotherapies for nicotine
dependence have largely targeted nicotinic acetylcholine receptors (nAChRs), as
activation of these receptors by nicotine mediates the rewarding effects of tobacco
(Coe et al 2005, Polosa & Benowitz 2011, Rollema et al 2007, Xiao et al 2006).
However, the molecular mechanism underlying vulnerability to smoking relapse is
multifaceted (Polosa & Benowitz 2011). One avenue for development of new
therapeutics is reassessing the symptomology of individuals undergoing nicotine
withdrawal. For example, patients with smoking-related disease, such as chronic
obstructive pulmonary disease, often present with increased cellular oxidative
stress levels. These observed effects may be the result of inhaled oxidants present
in cigarette smoke (Babizhayev 2014). However, individuals attempting to quit
smoking may also lose nicotine’s neuroprotective effects (Barreto et al 2014, Lu et
al 2017, Ross & Petrovitch 2001, Tariq et al 2005) . For example, clinical studies
have

shown

nicotine

transdermal

patches
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to

be

neuroprotective

in

neurodegenerative diseases such as Alzheimer’s (Newhouse et al 2012, Wilson
et al 1995) and Parkinson’s (Villafane et al 2007), two diseases with extensive ties
to inflammatory responses (Amor et al 2010). This would suggest that smoking
cessation, while reducing the inhaled level of oxidants, may also remove the
potential anti-inflammatory benefits of nicotine in the brain.
Microglia are highly specialized resident immune cells, which act as the
brain’s

homeostatic

sensor.

Their

constant

surveillance

of

the

brain

microenvironment enables them to detect and respond to homeostatic
perturbations by altering their own morphology in diverse ways depending on the
type of stimuli they sense. Such changes in microglial morphology are more
indicative of an imbalance in CNS homeostasis following an insult or injury and not
a particular activation phenotype (M1 pro-inflammatory phenotype or M2 antiinflammatory phenotype) as initially conceptualized (Ransohoff 2016, Salter &
Stevens 2017). Furthermore, studies have described microglia as critical elements
in synaptic remodeling (Miyamoto et al 2016, Weinhard et al 2018), as well as
learning and memory (Torres et al 2016) – processes prominently affected during
development of drug dependence (Kutlu & Gould 2016, Torregrossa et al 2011).
In addition to neuroplasticity-related events, microglia actively participate in
reactive oxygen species (ROS) generation (Lull & Block 2010). While ROS are key
intracellular signaling molecules for normal cell function, they can become toxic
when there is a chronic imbalance between oxidant and antioxidant signaling
within the cell, termed oxidative stress (Schieber & Chandel 2014). Since neurons
are particularly susceptible to oxidative insult, aberrant ROS production and
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signaling can significantly impact brain function and behavior (Li et al 2016, Seo et
al 2012). For example, correlative studies examining patients diagnosed with
Parkinson’s disease found a strong relationship between oxidative stress and
striatal neurodegeneration (Ikawa et al 2011). However, while the striatal
neurocircuit is a major site for neuroadaptive events underlying addictive
processes (Yager et al 2015), the effects of nicotine withdrawal on microglia
phenotype and related ROS homeostasis in this region are unknown.
The striatum is a heterogeneous structure with two distinct sub-regions – the
caudate-putamen, which contributes to motor functions and movement, and the
nucleus accumbens, which is key for motivation and reward processes (Yager et
al 2015). Our lab (Fisher et al 2017, Turner et al 2014) and others (Lee et al 2015,
Manhaes et al 2008) have shown that anxiety is a discrete, quantifiable symptom
of nicotine withdrawal, which has been shown to directly impact smoking relapse
in humans (Piper et al 2011). Previous studies in humans have demonstrated the
contribution of mesolimbic dopamine signaling in the nucleus accumbens to
anxiety-related processes (Kim et al 2008, Levita et al 2012, Lorberbaum et al
2004). Further, chronic stress studies have reported increased levels of oxidative
stress markers in other parts of the mesolimbic circuitry to coincide with increased
anxiety-like behavior (Patki et al 2013, Salim et al 2010). However, it is unknown
whether nicotine withdrawal elicits changes in microglial morphology and function,
and whether these changes directly impact anxiety. Our studies are the first to
report nucleus accumbens-specific alterations in microglial morphology and ROS
homeostasis. Further, we demonstrate compelling evidence that these microglia-
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related effects are critical mediators of anxiety-like behaviors in mice during
nicotine withdrawal.

2.3

MATERIALS AND METHODS

Animals
For the majority of the experiments described, male B6/129SF1 and B6/129PF1
mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA; 8 -10
weeks of age; 20 - 31 g). Magnetic activated cell sorting (MACS) experiments
examining cell-type specific mRNA expression utilized male B6/129 mice bred in
house (8 -10 weeks of age; 20 - 31 g). All mice were housed in groups of two to
four, and randomly assigned to treatment conditions. They were maintained on a
12-h light/dark cycle with food and water ad libitum in accordance to the University
of South Carolina Animal Care and Use Committee. All behavioral testing sessions
were conducted between the 0900 and 1300 hours.

Osmotic drug delivery and treatment
(-)-Nicotine tartrate (MP Biomedicals, Solon, OH, USA) was dissolved in sterile
0.9% sodium chloride solution, and then infused subcutaneously via osmotic
minipumps (Alzet model 2002; DURECT Corporation, Cupertino, CA, USA) at a
dose of 18 mg/kg/day for 15 days. The control group was infused with saline for
the same period of time. Chronic treatment with nicotine at this dose yields a
plasma level of approximately 0.3 μM in mice (reported as nicotine free base
molecular weight), a concentration comparable to that observed in human smokers
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consuming an average of 17 cigarettes a day (plasma levels between 0.06 - 0.31
μM) (Matta et al 2007). Prior to the start of surgery, mice were anesthetized with
isoflurane/ oxygen mixture (1 - 3%), and minipumps were inserted using aseptic
techniques. Surgical wounds were closed with 7 mm stainless steel wound clips
(Reflex, Cellpoint Scientific, Gaithersburg, MD, USA), after which mice were left to
recover on the recovery pad before they were returned to their individual cages.
After 14 days of chronic administration of either saline or nicotine via osmotic
minipumps, mice earmarked for withdrawal from chronic nicotine and their
assigned saline controls were subjected to spontaneous withdrawal by the removal
of their osmotic minipumps using a similar aseptic surgical approach as above.
Tissues were collected from mice after 48 h withdrawal.

Injection drug delivery and treatment
N-acetylcysteine (NAC) (A7250, Sigma-Aldrich, St Louis, MO, USA) was dissolved
in sterile 0.9% sodium chloride solution, adjusted to pH 7, and administered
intraperitoneally (IP) at a dose of 150 mg/kg per day for 4 days (24 h prior to
withdrawal, and each morning for the next 3 days). The administered NAC dose
was selected based on previously published studies (Cao et al 2012, Victor et al
2003). Post-withdrawal NAC injections were given 30 minutes before behavioral
testing. Mice not receiving NAC were injected with vehicle (sterile 0.9% sodium
chloride solution) during this treatment period.
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Microglia depletion via chow treatment
Plexxikon Inc. (Berkeley, CA) provided colony stimulating factor-1 receptor
(CSF1R) inhibitor, PLX5622, which was formulated in AIN-76A chow at a dose of
1200 ppm by Research Diets (New Brunswick, NJ). Control chow was also
provided. Male B6/129SF1 mice (8 weeks old) received either control chow or
PLX5622 chow for 7 days prior to withdrawal and all through 48 h withdrawal
period.

Open field test and locomotor activity
The open field test is an anxiety-related behavioral model, which also allows
simultaneous assay of overall locomotor activity levels in mice. All mice were
tested in this model at 24 h withdrawal timepoint. Test chambers were wiped with
70% ethanol in between tests to remove any scent cues left by the previous mouse.
The ethanol was allowed to dry completely before each testing, and every testing
session lasted for 15 minutes. For the analysis, Top Scan (Clever Sys Inc., Reston,
Virginia, USA) software was utilized to track and evaluate mouse movement. Prior
to tracking analysis for each mouse, a background profile was generated, and the
testing chamber was calibrated in arena design mode according to manufacturer’s
instructions. Software output for each individual test includes total distance moved
(in mm) and the time spent in the center (in %). These data were then normalized
to the saline/vehicle control group.
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Marble-burying test
The marble-burying test is an animal behavioral model of anxiety that has high
predictive value in detecting anxiolytic drugs. All mice were tested in this model at
48 h withdrawal timepoint. Mice were placed individually in small cages (29.0 cm
x 17.5 cm), in which 20 marbles had been equally distributed on top of mouse
bedding (5 cm deep). A lid was placed on top of the cage to prevent the mouse
from jumping out of the cage during the test. Mice were left undisturbed for 15
minutes, after which the number of buried marbles (those covered by bedding
three-quarters or more) was counted by an observer blinded to experimental
conditions.

Quantitative PCR
Quantitative reverse transcriptase PCR was performed as previously described
(Cleck et al 2008) on caudate putamen or nucleus accumbens samples across all
treatment groups. Briefly, RNA was isolated using the RNeasy Mini Kit (Qiagen,
Venlo, The Netherlands), and qPCR reactions were assembled using synthesized
complementary DNA, Thermo Scientific Maxima SYBR Green master mix along
with 100 nM primers (Integrated DNA Technologies, Inc., Coralville, Iowa, USA)
diluted to 4.3 nM final concentration. The mRNA levels were determined using the
2

−ΔΔCT

method (Livak & Schmittgen 2001) and target genes were normalized to

the housekeeping gene, hypoxanthine phosphoribosyltransferase (HPRT). All
gene expression values were normalized to their respective saline controls. Primer
sequences are available upon request.
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Western blot
Protein analysis was performed as described previously (Portugal et al 2012) on
nucleus accumbens samples of all treatment groups. Briefly, 20 μg of protein were
resolved in Any KD precast polyacrylamide gel (Bio-Rad Laboratories Inc.,
Hercules, CA, USA) and transferred to nitrocellulose membranes. Membranes
were incubated with LI-COR blocking buffer (LI-COR, Lincoln, NE, USA) for 1 h at
room temperature before reacting overnight at 4 oC with primary antibodies (Nox2
(1:1000, ab129068, Abcam Biotechnology, Cambridge, UK) and GAPDH (1:1000,
sc-32233, Santa Cruz Biotechnology, Santa Cruz, CA, USA)). After washing in
phosphate buffered saline-Tween-20, the blots were incubated in fluorescent
secondary antibodies (1:20000, LI-COR) in LI-COR blocking buffer for 1 h at room
temperature. Membranes were then washed, and immunolabeling detection and
densitometry measurements were performed using the LICOR Odyssey System
(LI-COR). Ratios of Nox2 (60 kD band) to GAPDH densities were calculated for
each sample and analyzed across conditions.

Protein carbonylation assay
Protein carbonyl derivatives were determined in caudate putamen and nucleus
accumbens samples of all treatment groups using OxiSelect Protein Carbonyl
Immunoblot Kit (Cell Biolabs, Inc., San Diego, CA, USA) following the
manufacturers details. Briefly, 20 μg of protein were resolved in Any KD miniprotean precast polyacrylamide gel (Bio-Rad Laboratories Inc., Hercules, CA,
USA) and transferred to nitrocellulose membranes. Membranes were processed
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for 2,4-dinitrophenylhydrazine (DNPH) derivatization by equilibrating them in Tris
buffered saline (TBS) containing 20% methanol, followed by washes in 2 N HCL,
incubation in 1X DNPH, and final washes in 2 N HCL and 50% methanol. DNPHtreated membranes were then incubated with LI-COR blocking buffer (LI-COR,
Lincoln, NE, USA) for 1 h at room temperature before reacting overnight at 4 oC
with primary antibodies (Anti-DNP (1:1000, Cell Biolabs, Inc.) and GAPDH
(1:1000, sc-32233, Santa Cruz Biotechnology, Santa Cruz, CA, USA)). After
washing in Tris buffered saline-Tween-20 (TBST), the blots were incubated with
fluorescent secondary antibodies (1:20000, LI-COR) in LI-COR blocking buffer for
1 h at room temperature. Membranes were then washed, and immunolabeling
detection and densitometry measurements were performed using the LICOR
Odyssey System (LI-COR). DNP signals were normalized to GAPDH densities for
each sample.

Immunohistochemistry and microglia morphological analysis
One brain hemisphere from each mouse was collected and fixed overnight in 4%
paraformaldehyde in PBS. Fixed brains were cryoprotected by leaving them
overnight in 15% sucrose, and then in 30% sucrose for 48 h. Cryoprotected brain
hemispheres were sectioned through the striatum at 45 microns and processed for
IBA1 immunohistochemistry. Briefly, cryosections were incubated in a rabbit antiIBA1 primary antibody overnight (1: 1,000; Wako Catalog No. 019-19741),
followed by a 2-h incubation in a goat anti-rabbit secondary (1:500, Jackson
ImmunoResearch Laboratories, West Grove, PA, USA). The signal was amplified
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with the avidin biotin complex (ABC; Vector Labs) method (1:500) and visualized
with Vector ® VIP peroxidase substrate to yield a purple reaction product. Images
were generated at 200X magnification using Leica DMI 3000B microscope (Leica
Microsystems Inc., Buffalo Groove, IL, USA) fitted with Leica DFC 290HD digital
camera. Leica LAS core software was used for image acquisition. Morphological
analyses were conducted with National Institutes of Health ImageJ software. For
IBA1-positive cell count/ density, cell area, and cell perimeter measurements,
images were converted from RGB to 16-bit format before applying a threshold and
subsequent binary mask. Objects within each masked image were then scanned,
counted, and measured using the “Analyze Particles” command. Parameters for
analysis of IBA1-positive cells were set in pixel units excluding any object under
400±100 or above 4500±1000 square pixel units. Objects positioned at the edge
of the image field were excluded. For analysis of cell process count and length,
primary processes extending directly from the cell body and no shorter than 5
microns in length were counted and measured. 5-6 IBA1-positive cells per image
field were analyzed for average process count and length measurements. For all
morphological analyses, final measurements were reported in microns (resolution
of 6.2 pixels per micron).

Isolation of nucleus accumbal microglia and astrocytes by magnetic
activated cell sorting (MACS)
Nucleus accumbal tissues were diced with a sterile scalpel into small pieces in a
sterile petri dish containing 2 ml of cold Hank’s buffered saline solution (HBSS,
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minus Ca2+, Mg2+; Life Technologies Corporation, Grand Island, NY, USA). This
suspension was transferred into a 15 ml centrifuge tube, and then, spun at 300Xg
for 2 minutes at 4 oC. Supernatant was discarded, and tissue was processed into
single-cell suspension by enzyme dissociation using Miltenyl’s adult brain
dissociation kit (Miltenyl Biotec Inc., Auburn, CA, USA) according to the
manufacturer’s instructions. Following complete dissociation, cell suspension was
applied to pre-wet MACS Smart Strainer (70 μm; Miltenyl Biotec Inc., Auburn, CA,
USA), and the flow through was processed for microglia labeling with CD11b+
microbeads (Miltenyl Biotec Inc., Auburn, CA, USA). Cells were washed with 2 ml
0.5% BSA in PBS buffer and centrifuged at 300Xg for 10 minutes at 4 oC for
removal of any unbounded beads from the pellet. Cell pellet was re-suspended in
500μl 0.5% BSA in PBS buffer, and then applied onto a prepped MACS MS column
attached to an OctoMACS magnetic separator (Miltenyl Biotec Inc., Auburn, CA,
USA). Flow through containing unlabeled cells was collected first, and CD11b+
microglia were then collected by flushing out the magnetically labeled cells in the
column into a microcentrifuge tube following the removal of the column from the
magnetic separator. The flow through was immediately processed for astrocyte
labeling using anti-ACSA-2 microbead kit (Miltenyl Biotec Inc., Auburn, CA, USA)
according to the manufacturer’s instructions. In a similar way to the magnetic
separation step in CD11b+ microglia isolation, ACSA-2+ astrocytes were also
purified and collected.
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Behavioral and molecular data analyses
Results are presented as mean ± SEM. For behavioral data, statistical differences
between groups were determined using two-way ANOVA followed by multiple twostage linear step-up procedure of Benjamini, Krieger and Yekutieli multiple
comparisons test. For molecular data, statistical differences between groups were
determined using either one-way or two-way ANOVA followed by Bonferroni’s or
Tukey’s HSD multiple comparison test. All statistical analyses were done in
GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA, USA).

2.4

RESULTS

Chronic nicotine and withdrawal alter microglial morphology in the nucleus
accumbens.
Morphological changes and release of pro-inflammatory cytokines are canonical
features of activated microglia (Bollinger et al 2016, Ding et al 2017, Qin et al
2004). To evaluate both features during chronic nicotine and withdrawal, mice
were administered saline or nicotine (18 mg/kg/day) via osmotic minipump
implantation, and at 2 weeks, a 48-h withdrawal was initiated by removal of
implanted pumps in mice earmarked for nicotine withdrawal and their saline
controls (Figure 2.1a). Our evaluation of striatal microglia morphology revealed
region-specific alterations following chronic nicotine and withdrawal. In the nucleus
accumbens of chronic nicotine and withdrawal mice, there were more microglia
with larger cell area (F = 18.24, p < 0.0001, ANOVA; Saline versus Chronic nicotine
mice: p < 0.0001, Saline versus Nicotine withdrawal mice: p = 0.0169, Post-hoc
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analyses), larger cell perimeter (F = 6.390, p = 0.0018, ANOVA; Saline versus
Chronic nicotine mice: p = 0.0026, Sal versus Nicotine withdrawal mice: p =
0.0254, Post-hoc analyses), but not process length (F = 1.331, p = 0.2654,
ANOVA) compared to their saline counterparts; however, in the caudate putamen,
we observed differences only between the microglial process length of chronic
nicotine and withdrawal mice (Cell area: F = 2.917, p = 0.0547, ANOVA; Cell
perimeter: F = 1.121, p = 0.3264, ANOVA; Process length: F = 3.697, p = 0.0256,
ANOVA; Saline versus Chronic nicotine mice: p = 0.1848, Sal versus Nicotine
withdrawal mice: p = 0.6310, Chronic nicotine versus Nicotine withdrawal mice: p
= 0.0292, Post-hoc analyses) (Figure 2.1b – c, i - iii). While these data show that
chronic nicotine and withdrawal induce microglia activation in the nucleus
accumbens, our microglial process length data suggest that the observed
activation phenotype may be early in the microglia activation spectrum. Next, we
evaluated mRNA expression levels of TNFα and IL1β – pro-inflammatory cytokines
associated with microglia activation, and our qPCR results revealed a differential
mRNA profile of these cytokines in chronic nicotine and withdrawal mice. In the
nucleus accumbens, TNFα (F = 8.429, p = 0.0009, ANOVA; Saline versus Nicotine
withdrawal mice: p = 0.0032, Chronic nicotine versus Nicotine withdrawal mice: p
= 0.0015, Post-hoc analyses) and IL1β (F = 6.698, p = 0.0027, ANOVA; Saline
versus Nicotine withdrawal mice: p = 0.0179, Chronic nicotine versus Nicotine
withdrawal mice: p = 0.0023, Post-hoc analyses) mRNA levels were elevated in
the nicotine withdrawal mice compared to chronic saline and nicotine counterparts,
suggesting a muted pro-inflammatory signal during chronic nicotine treatment. In
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contrast, in the caudate-putamen, there was a significant decrease in IL1β mRNA
expression (F = 3.903, p = 0.0269, ANOVA; Saline versus Nicotine withdrawal
mice: p = 0.0361, Chronic nicotine versus Nicotine withdrawal mice: p = 0.0415,
Post-hoc analyses), but no significant change in TNFα mRNA expression (F =
3.140, p = 0.0538, ANOVA) between treatment groups (Figure 2.1d and e). Taken
together, these results demonstrate that chronic nicotine and withdrawal induce
microglial activation with distinct molecular features in the nucleus accumbens.

Nicotine withdrawal induces reactive oxygen species in the nucleus
accumbens.
Given that excessive production of ROS is often associated with microglial
activation (Ding et al 2017), we directly examined ROS generation in the nucleus
accumbens and caudate putamen of saline, chronic nicotine, and nicotine
withdrawal mice using a protein carbonylation assay. Carbonylated proteins are
well-established markers for oxidative stress because they are representative
products of protein oxidation, which occurs either by direct or indirect reaction of a
protein with ROS or secondary by-products of oxidative stress (Suzuki et al 2010b,
Zhang et al 2013) (Figure 2.2a; Protein and arrow icons were downloaded from
Reactome (Sidiropoulos et al 2017)). In agreement to our previous observations
of TNFα and IL1β mRNA levels, we found that nicotine withdrawal animals had
increased levels of carbonylated proteins (F = 9.125, p = 0.0004, ANOVA; Saline
versus Nicotine withdrawal mice: p = 0.0012, Chronic nicotine versus Nicotine
withdrawal mice: p = 0.0019, Post-hoc analyses) in the nucleus accumbens
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compared to the chronic saline and nicotine equivalents, while there were no
changes (F = 0.3290, p = 0.7247, ANOVA) between treatment groups in the
caudate putamen (Figure 2.2b and c). These data further reinforce that the
observed dissimilar pro-inflammatory signaling during chronic nicotine and
withdrawal is specific to the nucleus accumbens.

N-acetylcysteine prevents microglial signaling, but not activation, in the
nucleus accumbens during nicotine withdrawal.
While we have shown that nicotine withdrawal induces ROS generation in the
nucleus accumbens, it is unclear whether altered microglial morphology and
signaling during nicotine withdrawal can be attenuated by ROS scavenging. To
examine this, we utilized N-acetylcysteine (NAC), a well-described antioxidant
(Aruoma et al 1989, Dekhuijzen 2004, Sun 2010). In this experiment, animals were
administered saline or nicotine (18 mg/kg/day) via osmotic minipump implantation,
and at 2 weeks, a 48 h withdrawal was initiated by removal of implanted pumps in
animals earmarked for nicotine withdrawal and their saline controls. A day prior to
withdrawal and each morning for the next 3 days, all animals received either
vehicle or NAC (150 mg/kg per day) injection intraperitoneally (Figure 2.3a). First,
we evaluated the impact of NAC on nicotine withdrawal-induced pro-inflammatory
cytokines in the nucleus accumbens. Our TNFα qPCR results show that there was
a main effect of nicotine withdrawal (F(2, 88) = 13.51, p = 0.0001, ANOVA), but no
main effect of NAC injection (F(1, 88) = 0.02802, p = 0.8674, ANOVA) or an
interaction effect (F(2, 88) = 2.503, p = 0.0876, ANOVA). Post-hoc analyses
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demonstrated vehicle-treated nicotine withdrawal mice showed increased TNFα
mRNA expression in the nucleus accumbens compared to their nicotine
counterparts and saline controls (p = 0.0040; p = 0.0031, respectively). In addition,
TNFα message also increased in the nucleus accumbens of the NAC-treated
nicotine withdrawal mice compared to vehicle-treated nicotine mice and saline
controls (p = 0.0476; p = 0.0408, respectively) (Figure 2.3b). Our IL1β mRNA
expression data show there was a main effect of nicotine withdrawal (F(2, 86) =
6.026, p = 0.0036, ANOVA), but no main effect of NAC injection (F(1, 86) = 3.269,
p = 0.0741, ANOVA) or an interaction effect (F(2, 86) = 1.041, p = 0.3575,
ANOVA). Post-hoc analyses demonstrated that while vehicle-treated nicotine
withdrawal mice showed increased IL1β mRNA expression in the nucleus
accumbens compared to their nicotine counterparts and saline controls (p =
0.0029; p = 0.0221, respectively), IL1β message in the nucleus accumbens of the
NAC-treated nicotine withdrawal mice was not significantly different from their
vehicle-treated nicotine mice and saline controls (Figure 2.3c). Similarly, analysis
of carbonylated protein levels in the nucleus accumbens indicated a main effect of
nicotine withdrawal (F(2, 84) = 7.068, p = 0.0015, ANOVA), but no main effect of
NAC treatment (F(1, 84) = 1.148, p = 0.2870, ANOVA) or an interaction effect (F(2,
84) = 2.929, p = 0.0589, ANOVA). Post-hoc analyses showed that vehicle-treated
nicotine withdrawal mice had increased amounts of carbonylated proteins
compared to their nicotine equivalents and saline controls (p = 0.0049; p = 0.0028;
respectively). In contrast, levels of this ROS marker were not significantly different
between NAC-treated nicotine withdrawal mice and their respective vehicle-
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treated nicotine mice and saline controls (p = 0.7903; p = 0.7941) (Figure 2.3d and
e). Next, we evaluated the impact of NAC on WD-induced microglial activation,
and we observed that the nucleus accumbens level of microgliosis was unchanged
with respect to the cell area (t(274) = 0.09383, p = 0.9253, unpaired t-test), cell
perimeter (t(275) = 0.8845, p = 0.3772, unpaired t-test) and process length (t(189)
= 0.5959, p = 0.5520, unpaired t-test) between nicotine withdrawal mice and their
NAC-treated counterparts (Figure 2.4a and b, i - iii). Overall, these data show that
while NAC treatment has no impact on morphological hallmarks of microglial
activation, it was able to attenuate nicotine withdrawal-induced ROS in the nucleus
accumbens.

N-acetylcysteine

attenuates

nicotine

withdrawal-induced

anxiogenic

behavior in mice.
Given recent studies supporting the role of the nucleus accumbens in anxietyrelated disorders (Kim et al 2008, Levita et al 2012), we evaluated NAC effect and
withdrawal from chronic nicotine in two well-validated behavioral models of anxiety,
the marble-burying (MB) test and the open field (OF) test. These behavioral tests
were conducted 30 minutes post-injection at 24-h (OF test) and 48-h (MB test)
withdrawal time points (refer to Figure 2.3a). In the MB test, there was a significant
interaction between the main effects (Treatment effect: F(2, 90) = 1.350, p =
0.2644, ANOVA; Injection effect: F(1,90) = 1.002, p = 0.3195, ANOVA; Interaction:
F(2, 90) = 5.642, p = 0.0049, ANOVA). Post-hoc analyses showed that vehicletreated nicotine withdrawal animals buried more marbles than their saline controls
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(q = 0.0330), as well as their nicotine and NAC-treated equivalents (q = 0.0148; q
= 0.0148, respectively) (Figure 2.5a), indicative of an anxiogenic effect. In the OF,
there was a significant interaction between the main effects (Treatment effect: F(2,
90) = 2.524, p = 0.0858, ANOVA; Injection effect: F(1,90) = 0.1591, p = 0.6910,
ANOVA; Interaction: F(2, 90) = 5.079, p = 0.0081, ANOVA). From our post-hoc
analyses, we discovered that vehicle-treated nicotine withdrawal animals spent
less time in the center of the arena compared to their nicotine counterparts and
saline controls (q = 0.0042; q = 0.0042), indicating an anxiogenic response. This
is in contrast to NAC-treated nicotine withdrawal animals, which were not
significantly different from vehicle-treated nicotine mice and their saline controls
(Figure 2.5b and c). Further, these effects were not due to alterations in locomotor
activity, as there were no differences in distance traveled between any of the
treatment groups (Treatment effect: F(2, 91) = 2.713, p = 0.0717, ANOVA; Injection
effect: F(1, 91) = 0.08425, p = 0.7723, ANOVA; Interaction: F(2, 91) = 2.379, p =
0.0984, ANOVA) (Figure 2.5d). Altogether, these results suggest a role for nucleus
accumbal oxidative stress in the development of nicotine withdrawal-related
anxiety.

Microglia-related NADPH oxidase 2 is increased in the nucleus accumbens
during nicotine withdrawal.
Among the many molecular mechanisms of intracellular ROS generation (Orient
et al 2007), the NADPH oxidase (Nox) system is a major source of intracellular
ROS production in the brain (Guilarte et al 2016, Rastogi et al 2016). Therefore, to
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evaluate whether this system is the molecular source of WD-induced ROS, we
examined the nucleus accumbens for changes in the primary Nox isoforms
expressed in the brain. Quantitative PCR analysis of Nox1 (Treatment effect: F(2,
91) = 0.7784, p = 0.4622, ANOVA; Injection effect: F(1, 91) = 0.7397, p = 0.3920,
ANOVA; Interaction: F(2, 91) = 0.4887, p = 0.6150, ANOVA) and Nox4 (Treatment
effect: F(2, 92) = 0.1001, p = 0.9049, ANOVA; Injection effect: F(1, 92) = 0.01189,
p = 0.7310, ANOVA; Interaction: F(2, 92) = 1.521, p = 0.2240, ANOVA) in the
nucleus accumbens showed no significant differences between treatment groups.
However, qPCR analyses of Nox2, which is primarily expressed in the microglia
(Zhang et al 2016), showed significant treatment and interactive effects (Treatment
effect: F(2, 87) = 9.726, p = 0.0002, ANOVA; Injection effect: F(1, 87) = 3.563, p =
0.0624, ANOVA; Interaction: F(2, 87) = 3.731, p = 0.0279, ANOVA). Post-hoc
analyses showed that Nox2 mRNA expression was significantly increased in the
nucleus accumbens of vehicle-treated nicotine withdrawal mice compared to their
saline controls (p = 0.0006), as well as their nicotine and NAC-treated equivalents
(p = 0.0002; p = 0.0221, respectively) (Figure 2.6a, i - iii). Of note, no significant
differences in Nox2 mRNA expression were observed in the caudate putamen
(Treatment effect: F(2, 86) = 0.5177, p = 0.5977, ANOVA; Injection effect: F(1, 86)
= 0.1992, p = 0.6565, ANOVA; Interaction: F(2, 86) = 1.142, p = 0.3238, ANOVA)
(Figure 2.6b). Further analyses investigating Nox2 protein show there was a main
effect of nicotine withdrawal (F(2, 79) = 5.405, p = 0.0063, ANOVA), but no main
effect of NAC injection (F(1, 79) = 0.01378, p = 0.9068, ANOVA) or an interaction
effect (F(2, 79) = 0.5078, p = 0.6038, ANOVA). Post-hoc analyses demonstrated
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that while vehicle-treated nicotine withdrawal mice showed increased Nox2 protein
expression in the nucleus accumbens compared to their saline controls (p =
0.0138), Nox2 levels in the nucleus accumbens of NAC-treated nicotine withdrawal
mice was not significantly different from the levels in the vehicle-treated nicotine
mice and their saline controls (p = 0.9000; p = 0.1070, respectively) (Figure 2.6c).
Altogether, these data support that increased nucleus accumbal Nox2 during
nicotine withdrawal contributes significantly to ROS production underlying nicotine
withdrawal-related anxiety. Given that previous studies investigating Nox
expression in brain cell-types induced Nox with lipopolysaccharide or examined
Nox in pathological states (Nayernia et al 2014), we evaluated the enrichment of
Nox isoforms at baseline in both neuronal and glial cell-types. We utilized magnetic
activated cell sorting (MACS) for isolation and purification of cell-types in nucleus
accumbens tissue. The purified cells were validated and investigated for Nox
expression using qPCR. Our validation of microglia showed that CD11b+ (F =
344.1, p < 0.0001, ANOVA; Total Homogenate versus CD11b+ microglia: p <
0.0001, Post-hoc analysis), Tmem119 (F = 120.2, p < 0.0001, ANOVA; Total
Homogenate versus CD11b+ microglia: p < 0.0001, Post-hoc analysis), and
P2ry12 (F = 75.70, p < 0.0001, ANOVA; Total Homogenate versus CD11b+
microglia: p < 0.0001, Post-hoc analysis) were highly enriched in CD11b+ microglia
compared to total homogenate; however, there was no significant difference in
expression of these microglia markers in total homogenate compared to ACSA II
astrocytes, liver, neurons and oligodendrocytes (Figure 2.7a, i - iii). While Nox1 (F
= 6.452, p = 0.0032, ANOVA; Total Homogenate versus Liver: p = 0.0034, Post-
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hoc analysis) and Nox4 (F = 10.31, p = 0.0006, ANOVA; Total Homogenate versus
Liver: p = 0.0021, Post-hoc analysis) mRNA analyses showed significant
enrichment in the liver compared to total homogenate, there were no significant
differences between total homogenate and the evaluated brain cell-types (Figure
2.7b, i and ii). In contrast, Nox2 mRNA is significantly enriched in both microglia (F
= 9.995, p = 0.0002, ANOVA; Total Homogenate versus CD11b+ microglia: p =
0.0005, Post-hoc analysis) and liver (F = 9.995, p = 0.0002, ANOVA; Total
Homogenate versus Liver: p < 0.0305, Post-hoc analysis) compared to total
homogenate, which is not significantly different from ACSA II astrocytes, neurons
and oligodendrocytes (Figure 2.7b, iii). Altogether, these data suggest that
microglia-related Nox2 significantly contributes to excessive nucleus accumbal
ROS generation and associated anxiety-like behavior during nicotine withdrawal.

Microglia depletion blocks increases in nicotine withdrawal-induced NADPH
oxidase 2 and reactive oxygen species in the nucleus accumbens and
attenuates nicotine withdrawal-related anxiety
Microglia are actively involved in the brain’s functional organization (Perry et al
2010, Salter & Stevens 2017), which can be altered by chronic drug use or
withdrawal. Our studies have demonstrated that withdrawal from chronic nicotine
use, but not chronic nicotine treatment, elicits microglial morphological changes
accompanied with pro-inflammatory signals in the nucleus accumbens (Figure 2.1,
b - e). Therefore, to understand the contribution of this microglial phenotype in the
development of withdrawal-related anxiety, we pharmacologically knocked down
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microglia in saline and nicotine withdrawal animals using PLX5622, which is a
colony stimulating factor-1 receptor (CSF1R) inhibitor. Both saline and nicotine
withdrawal animals were fed either control- or PLX5622-chow 7 days after
receiving chronic saline or nicotine treatment via osmotic minipump implantation.
Withdrawal from chronic saline or nicotine lasted 48 h. OF and MB test were
conducted at 24-h and 48-h withdrawal time points respectively (Figure 2.8a). Our
evaluation of microglia density in the nucleus accumbens showed a significant
main effect of PLX5622 chow and an interaction effect (Treatment effect: F(1, 17)
= 0.02218, p = 0.8834, ANOVA; Chow effect: F(1, 17) = 54.39, p < 0.0001, ANOVA;
Interaction: F(1, 17) = 4.705, p = 0.0445, ANOVA). Post-hoc analyses showed
significant decrease in Iba1+ cells / mm2 (Saline Control-chow versus Saline
PLX5622-chow: p <0.0001; Nicotine withdrawal Control-chow versus Nicotine
withdrawal PLX5622-chow: p = 0.0107) in the nucleus accumbens of the
PLX5622-treated animals compared to their controls (Figure 2.8b, i and ii). Further,
we evaluated microglia depletion in the nucleus accumbens using well-validated
microglia markers. Both Tmem119 (Treatment effect: F(1, 34) = 0.06459, p =
0.8009, ANOVA; Chow effect: F(1, 34) = 917.4, p < 0.0001, ANOVA; Interaction:
F(1, 34) = 1.632, p = 0.2101, ANOVA) and P2ry12 (Treatment effect: F(1, 34) =
0.03939, p = 0.8439, ANOVA; Chow effect: F(1, 34) = 461.5, p < 0.0001, ANOVA;
Interaction: F(1, 34) = 0.2781, p = 0.6014, ANOVA) mRNA only showed significant
main effect of PLX5622 chow. Similar to observations with Iba1+ cells / mm2
quantitation, our post-hoc analyses revealed significant reduction in Tmem119
(Saline Control-chow versus Saline PLX5622-chow: p <0.0001; Nicotine

45

withdrawal Control-chow versus Nicotine withdrawal PLX5622-chow: p <0.0001)
and P2ry12 (Saline Control-chow versus Saline PLX5622-chow: p <0.0001;
Nicotine withdrawal Control-chow versus Nicotine withdrawal PLX5622-chow: p
<0.0001) mRNA expression in PLX5622-treated animals compared to their
controls (Figure 2.8c, i - ii). However, given that CSF1R are also expressed on
macrophages, we examined whether there could be involvement of infiltrating
macrophages in our study by comparing the expression profile of Tmem119 and
P2ry12 to C-C-chemokine receptor 2 (Ccr2), which has been previously described
by many studies as a critical element for trafficking and assembly of myeloid cells
in the brain (Mizutani et al 2012, Morganti et al 2015, Prinz & Priller 2010,
Saederup et al 2010). In the nucleus accumbens, our data showed an extremely
low Ccr2 expression compared to Tmem119 and P2ry12 in all treatment groups.
In addition, CSF1R inhibition did not reduce Ccr2+ macrophages compared to
controls in the nucleus accumbens (Figure 2.8d). Next, we examined the impact
of microglia depletion on Nox2 expression in the nucleus accumbens during
nicotine withdrawal. Similar to our validation of microglia depletion with microglia
markers, our Nox2 qPCR analyses showed a significant chow effect (Treatment
effect: F(1, 32) = 4.077, p = 0.0519, ANOVA; Chow effect: F(1, 32) = 20.10, p <
0.0001, ANOVA; Interaction: F(1, 32) = 3.29, p = 0.0791, ANOVA). Post-hoc
analyses showed that Nox2 mRNA expression was significantly increased in the
nucleus accumbens of control-chow nicotine withdrawal mice compared to their
saline controls (p = 0.0417) and PLX5622-chow equivalents (p = 0.0006) (Figure
2.9a). Furthermore, we evaluated the effect of microglia knockdown on nicotine
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withdrawal-induced ROS in the nucleus accumbens. We found a significant
interactive effect between treatment and chow (Treatment effect: F(1, 31) = 1.661,
p = 0.2070, ANOVA; Chow effect: F(1, 31) = 2.371, p = 0.1337, ANOVA;
Interaction: F(1, 31) = 4.447, p = 0.0431, ANOVA). Similar to Nox2 mRNA
evaluation in these animals, our post-hoc analyses showed an increase in
carbonylated protein in the nucleus accumbens of control-chow nicotine
withdrawal mice compared to their saline controls (p = 0.0412) and PLX5622-chow
counterparts (p = 0.0270) (Figure 2.9b, i and ii). Finally, we assessed the
behavioral impact of microglia depletion during nicotine withdrawal. For MB test,
there was a significant main effect of nicotine withdrawal (Treatment effect: F(1,
35) = 4.637, p = 0.0383, ANOVA; Chow effect: F(1, 35) = 1.733, p = 0.1966,
ANOVA; Interaction: F(1, 35) = 1.937, p = 0.1728, ANOVA). While our post-hoc
analyses showed an increase in the amount of marbles buried by the control-chow
nicotine withdrawal mice compared to their saline controls (q = 0.0187), there was
no observable difference between the PLX5622-chow nicotine withdrawal mice
and their saline equivalents (q = 0.5630) (Figure 2.9c). Our OF analyses
demonstrated a significant main effects of nicotine withdrawal and PLX5622 chow
(Treatment effect: F(1, 35) = 19.18, p = 0.0001, ANOVA; Chow effect: F(1, 35) =
5.736, p = 0.0221, ANOVA; Interaction: F(1, 35) = 0.08795, p = 0.7685, ANOVA).
From our post-hoc analyses, we found that control-chow nicotine withdrawal mice
spent less time in the center of the arena compared to their PLX5622-chow
counterparts (q = 0.0031) and saline controls (q = 0.0487) (Figure 2.9, d and e).
There were no observed differences in distance moved between animals from all
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treatment groups (Figure 2.9f). Overall, these data show that microglia depletion
reduced aberrant nucleus accumbal oxidative signaling and associated anxiogenic
behaviors.

2.5

DISCUSSION

Altered microglial signaling and associated neuroinflammation are well known key
molecular events in the onset and progression of several neurodegenerative
diseases (Chen et al 2016, Cunningham 2013, Perry et al 2010); however, their
role in nicotine dependence has not been previously investigated. We show that
chronic nicotine and withdrawal trigger microglial morphological changes with
dissimilar activation phenotypes in the nucleus accumbens, and that the microglial
activation phenotype during nicotine withdrawal is of a pro-inflammatory pattern.
Further, we report elevated ROS levels in the nucleus accumbens only during
nicotine withdrawal and show evidence that Nox2, which is highly enriched in
microglia, is the major ROS-producing machinery. However, in contrast to our
findings in the nucleus accumbens, we show that both chronic nicotine and
withdrawal trigger none of these effects in the caudate putamen. Using a welldescribed antioxidant, we reveal a role for nucleus accumbal oxidative stress in
the development of nicotine withdrawal-related anxiety. More directly, after
depleting microglia to evaluate their role in connection to oxidative stress signals
in the nucleus accumbens during nicotine withdrawal, we show reduced Nox2
mRNA and ROS in the nucleus accumbens, as well as associated nicotine
withdrawal-related anxiety. Together, our study suggests that unlike other drugs of
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abuse such as cocaine, which directly elicits a microglial activation phenotype
associated with TNFα increase in the nucleus accumbens (Lewitus et al 2016a),
nicotine exposure results in unchanged nucleus accumbal levels of TNFα
regardless of microglial activation; however, acute withdrawal from nicotine
provokes microglial activation as well as increased TNFα levels in the nucleus
accumbens. Lastly, our data provide the first evidence that altered microglia
morphology and function significantly contribute to the development of anxiety-like
behavior during nicotine withdrawal.

Microglial Activation Phenotypes during Chronic Nicotine and Withdrawal in
the Striatum.
Microglia are central players in an increasing number of brain disorders (Salter &
Stevens 2017), and understanding their responsivity and role in nicotine
dependence becomes increasingly urgent. In our model, both chronic nicotine and
withdrawal induce remodeling of the highly adaptable resting microglia in the
nucleus accumbens, but not in the caudate putamen, suggesting that microglial
responsivity to drug cues may be shaped by the specialized role of their local CNS
environment. For example, a recent study examining microglia transcriptome
across the basal ganglia reported regional heterogeneity of resident microglia, and
indicated local cues as a critical mediator of microglia phenotype and their diversity
(De Biase et al 2017). In addition, this study also showed that genes associated
with oxidative signaling and ROS homeostasis are among the top 10 abundant
genes in nucleus accumbal microglia, but not microglia from other parts of the
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basal ganglia (De Biase et al 2017). This is consistent with our findings that show
disruption in ROS homeostasis in the nucleus accumbens, but not the caudate
putamen, during nicotine withdrawal. Another important finding is the dissimilar
expression of pro-inflammatory cytokines (TNFα, IL1β) and ROS in the nucleus
accumbens during chronic nicotine and withdrawal. This suggests distinct proinflammatory profile, which may be partly driven by the diverse phenotype of
activated microglia in both treatment conditions. In line with clinical studies that
have shown nicotine’s neuroprotective property in certain neurodegenerative
diseases (Newhouse et al 2012, Villafane et al 2007), our findings show an
absence of TNFα and IL1β mRNA induction during chronic nicotine treatment,
suggesting a muted pro-inflammatory response in the striatum. However, the
molecular attributes of activated microglia during withdrawal from chronic nicotine
are characteristic of the pro-inflammatory phenotype. Of note, the few studies
available on the role of microglia in drug dependence reported that microglial
activation and related pro-inflammatory effects were directly elicited by the drugs
of abuse examined, namely cocaine (Lewitus et al 2016a) and morphine
(Hutchinson et al 2009, Schwarz & Bilbo 2013). Similar to our findings, microglial
activation and elevated levels of pro-inflammatory signals in those studies were
limited to the nucleus accumbens, but our findings contrast with those earlier
studies in that activation of nucleus accumbal pro-inflammatory signals occur only
during withdrawal from nicotine and not due to exposure to nicotine itself. Microglia
are primarily involved in synaptic function and plasticity; however, their alteration
within the nucleus accumbens, which is a critical brain circuit for addictive
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processes, can enhance the development of aberrant synaptic connections and
plasticity underlying nucleus accumbal adaptive changes in drug dependency
(Grueter, Rothwell, & Malenka, 2012). Together, it is becoming clear that the
synaptic cues specific to the nucleus accumbens during chronic nicotine and
withdrawal influence its resident microglia signature.

Microglial NADPH Oxidase 2 Regulation in the Nucleus Accumbens during
Nicotine Withdrawal
NADPH oxidase (Nox) systems are primarily implicated in disease-related aberrant
ROS production (Panday et al 2015). Among the primary Nox isoforms in the brain
– Nox1, Nox2, and Nox4 (Ma et al 2017), our findings implicate Nox2 as the
primary source of excessive ROS in the nucleus accumbens during nicotine
withdrawal. Many studies have reported that Nox2 is highly enriched in microglia
compared to other brain cell-types (Guilarte et al 2016, Nayernia et al 2014, Zhang
et al 2014, Zhang et al 2016) and a previous study also provided additional
evidence showing that lipopolysaccharide (LPS) stimulation of BV2 microglial cell
lines resulted in Nox2-dependent ROS production (Huo et al 2011). In our study,
we find that among the brain cell-types, Nox2 is primarily expressed only in
microglia at baseline. Overall, this study suggests that microglia-related Nox2
contributes significantly to aberrant ROS levels in the nucleus accumbens during
nicotine withdrawal
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N-acetylcysteine

Effects

and

Anxiety-like

Behavior

during

Nicotine

Withdrawal.
Our behavioral findings provide a link between oxidative stress and anxiety-like
behavior during nicotine withdrawal. NAC treatment prior to nicotine withdrawal
precluded Nox2 induction and reduced ROS levels in the nucleus accumbens, a
brain region well described for its critical role in anxiety (Kim et al 2008, Levita et
al 2012, van der Kooij et al 2018). Together, NAC treatment results in attenuation
of anxiety-like behavior during nicotine withdrawal. While this interpretation relies
on NAC’s well-documented antioxidant effects, other mechanisms describing
NAC’s effects in nicotine dependence phenotypes have been previously described
(Gipson et al 2013, Knackstedt et al 2009). For example, Knackstedt et al (2009)
demonstrated that NAC treatment in smokers reduced the number of cigarettes
smoked by study participants. The authors attributed this effect in smokers to
NAC’s modulation of the astrocytic cystine-glutamate exchanger (xCT), which was
initially shown to be compromised in their preclinical studies investigating nicotine
seeking in rats (Knackstedt et al 2009). Of note, in their rodent experiment, while
xCT was downregulated in rats that self-administered nicotine, the xCT was
unchanged in animals that received nicotine via osmotic minipump, suggesting a
motivational rather than a pharmacological basis for changes in xCT during
nicotine exposure. Given that our findings are from mice treated with chronic
nicotine via osmotic minipump, our results are unlikely to be due to NAC’s
modulatory effects on the xCT, but more likely due to its extensively described
antioxidant activity (Aruoma et al 1989, Dekhuijzen 2004, Sun 2010). Furthermore,
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while our studies demonstrated that NAC treatment effectively attenuated
microglia-related ROS and the associated anxiety-like phenotypes, we also show
that NAC is ineffective in altering the microglial activation phenotype during
nicotine withdrawal. Given this limitation, combining NAC with therapeutics that
can inhibit microglial reprogramming to an activation phenotype, such as
minocycline (Suzuki et al 2010a, Zhu et al 2014), or those that can reverse the
activation phenotype may offer more effective treatment for smoking cessation.

Microglia Depletion and Anxiety-like Behavior during Nicotine Withdrawal
Several studies have implicated microglial function in anxiety-related disorders (Li
et al 2014, Stein et al 2017, Wang et al 2018); however, the role of microglia in
nicotine withdrawal-related anxiety is unknown. Our study shows that depletion of
microglia during nicotine withdrawal reduced Nox2 and ROS levels in the nucleus
accumbens, and consequently attenuated nicotine withdrawal-related anxiety.
These findings provide a strong link between microglia function and nicotine
withdrawal-related anxiety, and further reinforce the contribution of microglial Nox2
and associated aberrant ROS production in the nucleus accumbens to the
development of anxiety-like behavioral phenotype during nicotine withdrawal.

Perspectives on Future Smoking Cessation Pharmacotherapies
Currently, there are three FDA-approved pharmacotherapies for smoking
cessation:

varenicline (a nicotinic selective partial agonist), bupropion (a

norepinephrine-dopamine reuptake inhibitor), and nicotine replacement therapy
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(NRT, as patch, gum, etc.). While each of these therapeutics have quantifiable
success as smoking cessation aids, the best in class medication, varenicline,
results in only 40% abstinence success at 12 weeks and less than 20% at one
year post-quit (Gonzales et al 2006). This underscores the urgent need for new
drug targets in the development of new smoking cessation aids. We outline a
series of novel findings implicating neuroinflammatory responses during nicotine
withdrawal, arising not from the combustible contents of cigarettes, but from
nicotine withdrawal itself. This suggests that withdrawal from two of the current
smoking cessation aids, varenicline and NRT, may also alter neuroinflammatory
responses in the mesolimbic circuitry. Further, with e-cigarette use on the rise
particularly in adolescents and young adults, our findings lend mechanistic insight
into why vaping during adolescence promotes progression to combustible
cigarettes as adults (Leventhal et al 2015, Primack et al 2015). Long-term, further
investigation into modulators of microglial function during nicotine withdrawal
represents an untapped therapeutic avenue for smoking cessation.
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2.6

FIGURES
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Figure 2.1: Chronic nicotine and withdrawal induce different microglial activation
phenotypes in the nucleus accumbens. a. Experimental design. b. Representative
images of IBA1-positive microglia in the caudate putamen and nucleus accumbens of
saline (Sal), nicotine (Nic), and nicotine withdrawal (WD) mice. i) White dotted traces
delineate the caudate-putamen (dorsal) and nucleus accumbens (ventral); black dotted
traces indicate area where image iv – ix were taken. Scale bar = 1mm. ii) resting microglia,
and iii) activated microglia. Scale bar = 20μm. Caudate-putamen of iv) Sal mice, v) Nic
mice, and vi) WD mice. Nucleus accumbens of vii) Sal mice, viii) Nic mice, and ix) WD
mice. Scale bar = 100μm. c. Quantitation of IBA1-positive microglia morphology in the
caudate putamen and nucleus accumbens. i) Cell area, ii) Cell Perimeter, iii) Process
length. d. Bar charts showing TNFα mRNA expression in the nucleus accumbens and
caudate-putamen of Sal, Nic, and WD mice. e. Bar charts showing IL1β mRNA expression
in the nucleus accumbens and caudate-putamen of Sal, Nic, and WD mice. (Compared to
Sal – *P<0.05, **P<0.01, ****P<0.0001; Compared to Nic – #P<0.05, ##P<0.01; c: n =
minimum of 116 cells were quantified from 4-8 animals per treatment group; d, e: n=1224 per treatment group).
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Figure 2.2: Nicotine withdrawal induces reactive oxygen species in the nucleus
accumbens. a. Schematic diagram showing mechanism of ROS detection by protein
carbonylation assay (Protein and arrow icons were downloaded from Reactome
(Sidiropoulos et al., 2017)). b. Representative immunoblot showing the presence of
carbonylated protein (reactive oxygen species indicator) in Sal, Nic, and WD mice i)
nucleus accumbens, ii) caudate putamen. c. Quantitation of 2b. (Compared to Sal –
**P<0.01; Compared to Nic – ##P<0.01; c: n=6-19 per treatment group).
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Figure 2.3: N-Acetylcysteine attenuates nicotine withdrawal-induced reactive
oxygen species in the nucleus accumbens. a. Experimental design. b. Bar chart
showing nucleus accumbal mRNA expression of TNFα in vehicle- and NAC-treated Sal,
Nic and WD mice c. Bar chart showing nucleus accumbal mRNA expression of IL1β in
vehicle- and NAC-treated Sal, Nic and WD mice d. Representative immunoblot showing
the expression of carbonylated proteins in the nucleus accumbens of vehicle- and NACtreated Sal, Nic and WD mice e. Quantitation of 3d. (Compared to Sal-Vehicle – *P<0.05,
**P<0.01; Compared to Nic-Vehicle – ##P<0.01; b, c, and e: n=12-23 per treatment group).
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Figure 2.4: Nicotine withdrawal-induced microglia activation is unaltered by nacetylcysteine treatment. a. Representative images of IBA-1 positive microglia in the
nucleus accumbens of i) vehicle-treated, and ii) NAC-treated nicotine withdrawal mice.
Scale bar = 100μm. b. Quantitation of 4a. i) Cell area, ii) Cell Perimeter, iii) Process length.
(b: n = minimum of 87 cells were quantified from 4-5 animals per treatment group).
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Figure 2.5: N-acetylcysteine treatment is anxiolytic during nicotine withdrawal. a.
Marble-burying test: Bar graph showing the mean amount of marbles buried by vehicleand NAC-treated Sal, Nic and WD mice. b. Representative open field traces of vehicleand NAC-treated Sal, Nic and WD mice. c. Open field test: Bar chart showing percent time
spent in the center of the open field arena by vehicle- and NAC-treated Sal, Nic and WD
mice. d. Locomotor activity: Bar chart showing average distance moved in the open field
arena by vehicle- and NAC-treated Sal, Nic and WD mice. (Compared to Sal-Vehicle –
*q<0.05, **q<0.01; Compared to Nic-Vehicle – #q<0.05, ##q<0.01; Compared to WDVehicle $q<0.05; a, c, and d: n=9-23 per treatment group)
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Figure 2.6: Nicotine withdrawal increases Nox2 expression in the nucleus
accumbens. a. Bar graph showing quantitative PCR analysis of NOX isoforms (primarily
expressed in the brain) in the nucleus accumbens of vehicle- and NAC-treated Sal, Nic
and WD mice. i) Nox1, ii) Nox2, and iii) Nox4. b. Bar graph showing quantitative PCR
analysis of Nox2 mRNA expression in the caudate-putamen of vehicle- and NAC-treated
Sal, Nic and WD mice. c. Western blot image and quantification of nucleus accumbal Nox2
protein expression in vehicle- and NAC-treated Sal, Nic and WD mice. (Compared to SalVehicle – *P<0.05, ***P<0.001; Compared to Sal-NAC – &&P<0.01; Compared to NicVehicle – ###P<0.001; Compared to Nic-NAC – @@@P<0.001; Compared to WD-Vehicle –
$
P<0.05).
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Figure 2.7: Nox2 is expressed in microglia. a. Bar graph showing quantitative PCR
analysis of microglia markers in the liver, brain cell-types and tissue (Total homogenate).
i) CD11b, ii) Tmem119, and iii) P2ry12. b. Bar graph showing quantitative PCR analysis
of Nox isoforms in the liver, brain cell-types and tissue. i) Nox1, ii) Nox4, and iii) Nox2.
(Compared to Total homogenate – *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; a, b:
n=2-9 per treatment group).
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Figure 2.8: Inhibition of CSF1 receptor (CSF1R) depletes microglia in the nucleus
accumbens. a. Experimental design. b. i) Representative images of IBA1-positive
microglia in the nucleus accumbens of Control- and PLX5622-chow Sal, as well as their
WD equivalents. ii) Quantitation of 8bi. c. Bar graph showing quantitative PCR analysis of
microglia markers in the nucleus accumbens of Control- and PLX5622-chow Sal, as well
as their WD equivalents. i) Tmem119, and ii) P2ry12. d. Heatmap showing normalized
expression profile of Tmem119, P2ry12, and Ccr2 in the nucleus accumbens of Controland PLX5622-chow Sal, as well as their WD equivalents. (Compared to Sal-Control –
***P<0.001, ****P<0.0001; Compared to Sal-PLX5622 – ###P<0.001, ####P<0.0001;
Compared to WD-Control – $P<0.05, $$$$P<0.0001; bii: n=5 per treatment group; c, d:
n=10 per treatment group).
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Figure 2.9: Microglia depletion attenuates nicotine withdrawal-related anxiety. a. Bar
graph showing quantitative PCR analysis of Nox2 in the nucleus accumbens of Controland PLX5622-chow Sal, as well as their WD equivalents. b. i) Representative immunoblot
showing the expression of carbonylated proteins in the nucleus accumbens of Controland PLX5622-chow Sal, as well as their WD equivalents. ii) Quantitation of 9bi. c. Marbleburying test: Bar graph showing the mean amount of marbles buried by Control- and
PLX5622-chow Sal, as well as their WD equivalents. d. Representative open field traces
of Control- and PLX5622-chow Sal, as well as their WD equivalents. e. Open field test:
Bar chart showing percent time spent in the center of the open field arena by Control- and
PLX5622-chow Sal, as well as their WD equivalents. f. Locomotor activity: Bar chart
showing average distance moved in the open field arena by Control- and PLX5622-chow
Sal, as well as their WD equivalents. (Compared to Sal-Control – *P<0.05, **P<0.01;
Compared to Sal-PLX5622 – ##P<0.01, ###P<0.001; Compared to WD-Control – $P<0.05,
$$$
P<0.001; a, bii, c, e, and f: n=9-10 per treatment group)
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CHAPTER 3
TRANSCRIPTIONAL REMODELING IN RESPONSE TO CHRONIC
NICOTINE AND WITHDRAWAL IN ASTROCYTES AND
MICROGLIA1

________________________________
1

Adewale Adeluyi and Jill R. Turner. In preparation.
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3.1

ABSTRACT

Transcriptional programs are genomic regulatory code instructing the formation,
maintenance, and functions of diverse brain cell types and distinct brain structures.
Tissue- and cell type-specific evaluation of whole transcriptome can advance
current understanding of the role of genes in CNS health and disorders such as
nicotine dependence. Here, we performed whole transcriptome sequencing on
nucleus accumbens microglia, astrocytes, and its whole tissue at different
withdrawal timepoints (24 h and 48 h). We show temporally-dependent activation
of distinct gene programs in the nucleus accumbens during chronic nicotine and
withdrawal. Differential gene expression analysis suggests that chronic nicotine
treatment activates subset of genes that are neuroprotective while withdrawal from
nicotine provokes neuroinflammation and oxidative stress- related transcriptional
programs in the nucleus accumbens. Our cell type-specific RNA seq data support
our tissue-level observation. Gene programs associated with neuroinflammation
were suppressed in microglia following nicotine treatment while nicotine
withdrawal

triggers

microglial

pro-inflammatory

networks.

Further,

our

transcriptome data suggest astrocytes assume a reactive phenotype during
nicotine withdrawal. Finally, we find subset of genes that are enriched in nucleus
accumbens tissue and either of the nucleus accumbens cell types examined during
nicotine withdrawal. Taken together, our study provides the first insight into cell
type-specific and tissue-level transcriptional remodeling in the nucleus accumbens
during chronic nicotine and withdrawal.
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3.2

INTRODUCTION

Tobacco addiction impacts an estimated 1.2 billion people globally. While ability to
successfully quit smoking remarkably reduces smoking-related deaths and
diseases, about 80% of smokers attempting to quit fail (Benowitz 2010) due to the
effect of nicotine, which is the addictive component of tobacco. Smoking cessation
often leads to nicotine withdrawal symptoms, which usually manifest negative
behavioral signs a few hours after discontinuation of nicotine use. These
behavioral patterns are collections of affective and cognitive manifestations, which
are both predictors of smoking relapse (Ashare et al 2014). Chronic exposure to
drugs of abuse such as nicotine induces a number of neuroadaptations that result
in drug dependence (Koob & Kreek 2007, Turner et al 2014). Such adaptations in
neural circuits and associated functions are often required for maintenance of
nicotine dependence. While the molecular mechanisms underlying the long-lasting
nature of negative behaviors associated with nicotine dependence are not yet
completely understood, it is recently becoming clearer that changes in specific
gene programs in plastic neural circuits may underlie the development and
persistence of these behaviors (Brunzell et al 2003, Nestler 2008, Turner et al
2014).
The nucleus accumbens (NAc) is a heterogeneous structure that plays a
central role in the mesolimbic reward pathway. Chronic exposure to many drugs
of abuse including nicotine disrupt plasticity in the NAc circuitry, and these NAcrelated drug-induced neuroadaptations are known to underlie reward-related
behaviors, which markedly contributes to relapse vulnerability in drug dependency.
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Besides several frequently-reported neuroadaptive changes in the NAc following
chronic nicotine exposure, a few studies have demonstrated transcriptional
changes relating to CREB (cAMP-response element-binding protein) and FosB (a
Fos family protein) in this neurocircuitry (Brunzell et al 2009, Brunzell et al 2003,
Nestler 2008). Alteration of transcription factors such as CREB and FosB is one of
the common molecular mechanisms through which nicotine and other drugs of
abuse regulate gene expression, which may underlie the persistence of addictive
behaviors (Madsen et al 2012). Therefore, evaluation of NAc transcriptomic
changes during chronic nicotine and withdrawal may reveal tissue-level bulk gene
programs driving nicotine dependency. However, while quantification of tissuelevel transcriptome data may be a critical step towards advancing current
understanding of nicotine dependence, this level of transcriptomic analyses may
lack the actual resolution to better characterize the molecular phenotype
associated with addictive disorders. In the complex multicellular NAc structure,
there are neuronal and non-neuronal cell types such as astrocytes and microglia,
which all together interact to maintain the integrity and adaptation of this neural
circuitry (Allen & Barres 2009). Hence, evaluation of transcriptome-wide responses
at cell-type specific resolution will provide a better understanding and a less
complex

insight

into

NAc-related

molecular

processes

driving

nicotine

dependency.
In this study, we use RNA sequencing (RNA-seq) to capture temporal gene
expression changes in nucleus accumbens tissue during chronic nicotine and
withdrawal at different timepoints (24h and 48 h). Further, we explored
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transcriptomic changes in the nucleus accumbens at cell type-specific resolution
during chronic nicotine and 48 h withdrawal. We uncover multiple dysregulated
genes and molecular pathways that are related to nicotine dependence. Our study
provides the first direct evidence of transcriptome remodeling in the nucleus
accumbens at cell type-specific and tissue-level resolution during chronic nicotine
and withdrawal.

3.3

MATERIALS AND METHODS

Animals
Male B6/129SF1 mice were purchased from Jackson Laboratories (Bar Harbor,
ME, USA; 8 weeks of age; 20 – 31 g). Mice were housed in groups of four or five,
and randomly assigned to treatment conditions. They were maintained on a 12-h
light/dark cycle with food and water ad libitum in accordance to the University of
South Carolina Animal Care and Use Committee. All behavioral testing sessions
were conducted between the 0900 and 1300 hours.

Osmotic drug delivery and treatment
(-)-Nicotine tartrate (MP Biomedicals, Solon, OH, USA) was dissolved in sterile
0.9% sodium chloride solution, and then infused subcutaneously via osmotic
minipumps (Alzet model 2002; DURECT Corporation, Cupertino, CA, USA) at a
dose of 18 mg/kg/day for 15 days. The control group was infused with saline for
the same period of time. Chronic treatment with nicotine at this dose yields a
plasma level of approximately 0.3μM in mice (reported as nicotine free base
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molecular weight), a concentration comparable to that observed in human smokers
consuming an average of 17 cigarettes a day (plasma levels between 0.06 0.31μM) (Matta et al 2007). Prior to the start of surgery, mice were anesthetized
with isoflurane/ oxygen mixture (1-3%), and minipumps were inserted using
aseptic techniques. Surgical wounds were closed with 7mm stainless steel wound
clips (Reflex, Cellpoint Scientific, Gaithersburg, MD, USA), after which mice were
left to recover on the recovery pad before they were returned to their individual
cages. After 14 days of chronic administration of either saline or nicotine via
osmotic minipumps, mice earmarked for withdrawal from chronic nicotine and their
assigned saline controls were subjected to spontaneous withdrawal by the removal
of their osmotic minipumps using a similar aseptic surgical approach as above.
Tissues were collected from mice after 24 h or 48 h withdrawal.

Isolation of nucleus accumbal microglia and astrocytes by magnetic
activated cell sorting (MACS)
Nucleus accumbal tissues (10 pooled animals per N) from animals in the 48-h
withdrawal experiment were diced with a sterile scalpel into small pieces in a sterile
petri dish containing 2ml of cold Hank’s buffered saline solution (HBSS, minus
Ca2+, Mg2+; Life Technologies Corporation, Grand Island, NY, USA). This
suspension was transferred into a 15ml centrifuge tube, and then, spun at 300Xg
for 2mins at 4oC. Supernatant was discarded, and tissue was processed into
single-cell suspension by enzyme dissociation using Miltenyl’s adult brain
dissociation kit (Miltenyl Biotec Inc., Auburn, CA, USA) according to the
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manufacturer’s instructions. Following complete dissociation, cell suspension was
applied to pre-wet MACS Smart Strainer (70μm; Miltenyl Biotec Inc., Auburn, CA,
USA), and the flow through was processed for microglia labeling with CD11b+
microbeads (Miltenyl Biotec Inc., Auburn, CA, USA). Cells were washed with 2ml
0.5% BSA in PBS buffer and centrifuged at 300Xg for 10mins at 4oC for removal
of any unbounded beads from the pellet. Cell pellet was re-suspended in 500μl
0.5% BSA in PBS buffer, and then applied onto a prepped MACS MS column
attached to an OctoMACS magnetic separator (Miltenyl Biotec Inc., Auburn, CA,
USA). Flow through containing unlabeled cells was collected first, and CD11b+
microglia were then collected by flushing out the magnetically labeled cells in the
column into a microcentrifuge tube following the removal of the column from the
magnetic separator. The flow through was immediately processed for astrocyte
labeling using anti-ACSA-2 microbead kit (Miltenyl Biotec Inc., Auburn, CA, USA)
according to the manufacturer’s instructions. In a similar way to the magnetic
separation step in CD11b+ microglia isolation, ACSA-2+ astrocytes were also
purified and collected.

RNA extraction and purification
Total RNA was extracted and purified from nucleus accumbal CD11b+ microglia
and ACSA-2+ astrocytes using TRIzol (Invitrogen) and RNeasy Mini Kit (QIAGEN,
Valencia, CA) according to manufacturer’s instructions. Similarly, RNA was also
isolated and purified from nucleus accumbens tissues collected from animals in
the 24-h and 48-h withdrawal experiments.
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Library preparation
For nucleus accumbal CD11b+ microglia and ACSA-2+ astrocytes, RNA
sequencing libraries were prepared using the NuGEN Ovation RNA Ultra Low
Input kit (500pg minimum) (Tecan Genomics Inc., Redwood City, CA) while RNA
libraries for 24-h and 48-h withdrawal nucleus accumbens RNA samples were
prepared using NEBNext Ultra II RNA Directional RNA Library Prep kit (NEB,
Ipswich, MA).

RNA sequencing
Nucleus accumbal CD11b+ microglia and ACSA-2+ astrocytes libraries were
indexed and sequenced as 2X75bp paired-end reads over 4 lanes on an Illumina
HiSeq4000. For the 24-h and 48-h withdrawal experiment, nucleus accumbens
RNA libraries were indexed and sequenced as 2X75bp paired-end reads using
Illumina NextSeq500.

Sequencing data preprocessing analyses
To ensure there were no sequencing errors, demultiplexed fastq files from both
Illumina HiSeq4000 and Illumina NextSeq500 were checked for quality using
FastQC (v0.11.8). Reads that failed certain quality criteria were trimmed and
filtered

using

BBDuk

tool

(sourceforge.net/projects/bbmap/)

for

quality

improvement prior to the alignment step. Reads were then aligned to the mouse
genome (mm10, downloaded from iGenomes, Illumina) using STAR aligner (Dobin
et al 2013). Average input read counts were 53.75 million, 49.72 million, and 43.79
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million for CD11b+ microglia, ACSA-2+ astrocytes, and nucleus accumbens tissue
samples (24 h and 48 h) respectively. Average percentage of uniquely mapped
reads were 74.96%, 73.96%, and 88.15% for CD11b+ microglia, ACSA-2+
astrocytes, and nucleus accumbens tissue samples (24 h and 48 h) respectively.
Fragments counts were obtained using featureCounts (Liao et al 2014). Low read
counts were filtered prior to differential expression analysis.

Differential expression analyses
DESeq2 (Love et al 2014) was used to assess differential gene expression (DGE)
at a false discovery rate (FDR) < 0.2 and 0.25 for nucleus accumbens tissue
samples (24 h and 48 h) and cell types (CD11b+ microglia and ACSA-2+
astrocytes), respectively.

Principal component analysis and correlation analysis
Principal component analysis and correlation analysis using hierarchical clustering
function were performed to identify outliers in our samples.

Pathway Enrichment Analysis
Enrichr (Kuleshov et al 2016) was used in identifying and testing statistically
significant differentially expressed genes for overrepresentation in canonical
pathways.
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3.4

RESULTS

Experimental Design
Three separate set of experiments were performed with the nucleus accumbens –
the 24hWD, 48hWD, and 48hWD cell type-specific (astrocytes and microglia)
experiments. Each experiment has three treatment groups – Saline, Nicotine and
Withdrawal. The withdrawal mice in the 24hWD study were subjected to 24 h
withdrawal while in the 48hWD study, mice undergoing withdrawal from nicotine
were subjected to 48 h withdrawal. Nucleus accumbens tissues were utilized for
both 24WD and 48hWD studies; however, these tissues were processed for cell
sorting (microglia and astrocytes isolation/purification) in the cell type-specific
experiment. RNA seq libraries were constructed for each of these experiments,
and then sequenced (Figure 3.1a).

Transcriptional alterations in the nucleus accumbens during 24 h and 48 h
withdrawal from nicotine
Given that symptoms associated with nicotine withdrawal are usually intense within
24 - 48 h of abstinence (Stoker et al 2008), we examined temporal transcriptional
changes in the nucleus accumbens of mice that underwent withdrawal for 24 h or
48 h, in addition to their respective nicotine-treated and saline controls using RNAseq. For each of these treatment groups, we have 3 - 4 biological replicates. We
compare the transcriptome profile of 24hWD (n=3) and 48hWD tissue samples
(n=3) using a correlation matrix. Our data show that sample replicates of similar
withdrawal timepoints are highly correlated (Spearman ‘s rank correlation, mean r
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(24-h withdrawal replicates) = 0.93 ; Spearman ‘s rank correlation, mean r (48-h
withdrawal replicates) = 0.84) while replicates across timepoints have low
correlations (Spearman ‘s rank correlation, mean r (24-h withdrawal replicates vs
48-h withdrawal replicates) = 0.33 ) (Figure 3.1b ). These data suggest a minimal
overlap between differentially expressed genes (DEGs) at 24-h and 48-h
withdrawal timepoints. However, while temporal transcriptional changes are
expected during withdrawal from nicotine, it is important to note that our different
library preparation approaches (Ribosomal depletion for 24hWD experiment; PolyA enrichment for 48hWD experiment) may have introduced further transcriptome
variation between the 24hWD and 48hWD experiments. Next, we analyzed
transcriptomic changes between treatment groups by performing pairwise
differential gene expression (DGE) analysis (i.e. saline versus nicotine, saline
versus withdrawal, and nicotine versus withdrawal). Genes that we statistically
determined as differentially expressed are those with varying expression levels
between treatment groups at false discovery rate (FDR) less than 0.2. This FDR
cutoff was selected a priori since we do not expect large magnitude changes in
brain transcriptome during chronic nicotine treatment and withdrawal. In the
24hWD experiment, 207 genes (122 downregulated, 85 upregulated) were
differentially expressed between saline and nicotine groups, 1050 DEGs (565
downregulated, 485 upregulated) were revealed between saline and withdrawal
groups, and the expression levels of 75 genes (25 downregulated, 50 upregulated)
were altered between nicotine and withdrawal groups. However, in the 48hWD
experiment, DGE analysis revealed 11 DEGs (3 downregulated, 8 upregulated)
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between saline and nicotine groups, 653 DEGs (343 downregulated, 310
upregulated) between saline and withdrawal groups, and 1485 DEGs (549
downregulated, 936 upregulated) between nicotine and withdrawal groups. In
order to visualize and identify statistically significant DEGs at our designated cutoff
– fold changes (|log2FC| > 0.5) and adjusted p-values (FDR < 0.2), we generated
a color-coded volcano plot for both 24hWD and 48hWD experiments, indicating
upregulated genes in red and downregulated genes in blue (Figure 3.1c, i and ii).
Further, we constructed a heatmap showing pairwise comparison of statistically
significant DEGs between treatment groups. Our 24hWD data show there were no
statistically significant DEGs between saline and nicotine; however, 63 (22
downregulated, 41 upregulated) and 34 DEGs (5 downregulated, 29 upregulated)
were statistically significant between saline and withdrawal, and nicotine and
withdrawal groups, respectively (Figure 3.2a, i and ii.). Similarly, 48hWD pairwise
comparison

revealed

5

(2

downregulated,

3

upregulated),

359

(200

downregulated, 159 upregulated), 972 (295 downregulated, 677 upregulated)
statistically significant between saline and nicotine, saline and withdrawal, and
nicotine and withdrawal groups, respectively (Figure 3.2b, i - iii). Pathway
enrichment analysis of statistically significant DEGs indicates that genes involved
in overrepresented pathways such as cholinergic synapse (Gng4, Gng2, Adcy8),
glutamatergic synapse (Gng4, Gng2, Grik1, Adcy8), chemokine signaling (Gng4,
Gng2, Adcy8), oxidative stress (Gpx3), glutathione metabolism (Gpx3) and nuclear
receptors (Nr2f2, Rxrg) are upregulated during 24 h withdrawal (Figure 3.3a, i and
ii ). Similarly, in our 48hWD experiment, genes associated with enriched pathways

76

such as fatty acid beta oxidation (Lpl), adipogenesis (Lpl), Alzheimer’s disease
(Lpl), cholesterol metabolism (Lpl) and Tnf-alpha Nf-kβ signaling (Traip) were
upregulated following nicotine treatment (Figure 3.3bi). Further analyses also
revealed that genes upregulated during 48 h withdrawal timepoint are connected
to enriched pathways such as inflammatory response (Thbs1,Tnfrsf1a, Col1a1),
type II interferon signaling (Cybb, Isg15, Icam1, Ifit2, Prkcd, Gbp2b), microglia
pathogen phagocytosis (Cybb, Trem2, Rac2, Cyba, Itgb2), macrophage markers
(Rac2, Lyz2, Cd74, Cd83), complement and coagulation cascades (F2rl2, Itgb2,
Serpind1, Serping1, C3, C2, C7, Cfb), complement activation and classical
pathway (C3, C2, C7, C151) and TGFβ signaling (Lef1, Spp1, Smad9, Thbs1,
Zfp423, Bmp4) (Figure 3.3b, ii and iii). In contrast to the enriched pathways that
are altered during 24 h withdrawal timepoint, pathway analysis data at 48 h
withdrawal timepoint showed perturbation of microglia-related pathways.
Altogether, these data show temporal changes in nicotine withdrawal-induced
transcriptional programs in the nucleus accumbens.

Transcriptome remodeling in nucleus accumbal microglia and astrocytes
during 48 h withdrawal from nicotine
Non-neuronal cell types such as astrocytes and microglia are actively involved in
the formation, maintenance and adaptations of neural circuitry (Allen & Barres
2009). However, given possible disruption of molecular pathways related to
microglia during 48 h withdrawal (as demonstrated by our pathway analysis), we
evaluated nucleus accumbal microglia- and astrocyte-specific transcriptomic
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changes during chronic nicotine and 48 h withdrawal. For this experiment, we
generated 3 biological replicates (n =3) for each treatment – saline, nicotine and
withdrawal. To arrive at each n, we pooled dissected nucleus accumbens tissues
from 10 mice to improve our sample yield and maximize biological diversity. Then,
we utilized magnetic activated cell sorting (MACS) for isolation and purification of
microglia and astrocytes from pooled nucleus accumbens samples. Purified ACSA
II astrocytes and Cd11b+ microglia population were validated using quantitative
PCR. Our validation of microglia showed enrichment of microglia markers (Cd11b,
Tmem119 and P2ry12) in Cd11b+ microglia compared to total homogenate, liver
and other brain cell types (previously shown in Chapter 2, Figure 2.7a. i - iii).
Similarly, our astrocyte validation showed that astrocytes markers (Gfap and
S100β) are highly expressed in ACSA II astrocytes population compared to total
homogenate, liver and other brain cell types (Figure 3.4a, i and ii). RNA extracted
from purified cell populations were checked for quality and we found that our
samples’ RNA integrity number (RIN) range from 4.1 – 8.6. We constructed RNAseq libraries and performed deep sequencing on these libraries. To evaluate the
reproducibility of our sequencing data and conservation across biological
replicates, we computed correlations across all RNA-seq samples and found high
correlations among Cd11b+ microglia (Spearman’s rank correlation, mean r = 0.77)
or ACSA II astrocytes replicates (Spearman’s rank correlation, mean r = 0.70) and
low correlations between both cell type replicates (Spearman’s rank correlation,
mean r = 0.27). Hierarchical clustering of all RNA-seq samples in the correlation
matrix revealed two samples, one from Cd11b+ microglia replicates and another
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from ACSA II astrocytes replicates, as potential outliers (Figure 3.4b). This was
further supported by our principal component analysis (PCA) data (Figure 3.4c, i
and ii). Following outlier removal, we observed a tighter correlation within cell type
replicates and a more distinct separation between cell type replicates (Figure
3.4d). Then, we examined the purity of isolated brain cell types (microglia and
astrocytes) by probing transcriptome data for expression of cell type-specific
markers for microglia and astrocytes and found that these markers were highly and
specifically expressed in their corresponding cell types (Figure 3.4e). To analyze
microglia and astrocytes for treatment-related transcriptomic differences, we
performed pairwise DGE analysis and created a heatmap representation of DEGs
(cutoff = |log2FC| > 0.5, FDR < 0.25). In Cd11b+ microglia, 2458 genes (1009
downregulated, 1449 upregulated) were differentially expressed following nicotine
treatment; however, there was no significant transcriptomic alteration in ACSA II
astrocytes under the same treatment condition (Figure 3.5 a). Further, in Cd11b+
microglia, DGE analysis revealed 31 DEGs (5 downregulated, 26 upregulated)
between saline and withdrawal groups, and 32 DEGs (18 downregulated, 14
upregulated) between nicotine and withdrawal groups (Figure 3.5a, ii and iii).
However, in ACSA II astrocytes, 92 (42 downregulated, 50 upregulated) and 17
genes (13 downregulated, 4 upregulated) were differentially expressed between
saline and withdrawal, and nicotine and withdrawal groups, respectively (Figure
3.5b, i and ii). Pathway analysis of DEGs obtained from pairwise DGE analysis of
saline and nicotine Cd11b+ microglia shows that genes involved in enriched
pathways such as TYROBP causal network, microglia pathogen phagocytosis,
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type II interferon signaling, chemokine signaling, TGFβ signaling, IL-1 signaling,
macrophage markers, toll-like receptor signaling, inflammatory response, and
oxidative damage are downregulated while some of the upregulated genes are
involved in overrepresented pathways like nicotine addiction and hypothetical
network of drug addiction pathways (Figure 3.6ai). However, during 48 h
withdrawal, pathway analysis showed that upregulated Cd11b+ microglia DEGs
are involved in overrepresented pathways such as inflammation mediated by
chemokine and cytokine signaling, toll-like receptor signaling, cytokine-cytokine
receptor interaction, macrophage markers, and Tnf signaling (Figure 3.6a, ii and
iii). Furthermore, pathway analysis of ACSA II astrocytes DEGs showed that genes
that are upregulated during 48 h withdrawal are involved in overrepresented
pathways including biogenic amine synthesis, taurine and hypotaurine
metabolism, insulin secretion, butanoate metabolism, endocrine and other factorregulated calcium reabsorption, beta-alanine metabolism, and type I diabetes
mellitus (Figure 3.6b, i and ii). Taken together, these data suggest that nicotine
has a direct modulatory effect on microglia but not astrocytes. In addition, 48 h
withdrawal from nicotine provokes microglial pro-inflammatory signaling while vital
metabolic processes are disrupted in astrocytes.

Comparison of DEGs in nucleus accumbens bulk tissue, microglia and
astrocytes during chronic nicotine and withdrawal
To identify and visualize both unique and overlapping DEGs between nucleus
accumbens bulk tissue (24hWD and 48hWD experiments) and cell types
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(astrocytes and microglia) during chronic nicotine and withdrawal, we constructed
a Venn diagram and found that all DEGs resulting from pairwise DGE analysis of
saline and nicotine in nucleus accumbens tissue and cell type-specific experiments
were unique (no overlap) (Figure 3.7a). However, for pairwise DGE analysis of
saline and withdrawal, we found 8 overlapping DEGs (Btg2, Syt17, Nr4a3,
Slc6a11, Sparc, Gpr165, Nr2f2, Itih3) between 24hWD and 48hWD experiments,
1 (Scn4b) between 24hWD and astrocytes, 2 (Tsc22d3, Pdk4) between 24hWD
and microglia, 2 (Npas4, Pak6) between 48hWD and astrocytes, 3 (Mybpc1, Dio2,
Gjb6) between 48hWD and microglia, and 1 (6330403K07Rik) between astrocytes
and microglia experiments (Figure 3.7b). Further, two-way DGE analysis of
nicotine and withdrawal produced overlapping DEGs between 24hWD and 48hWD
(9 – Resp, Syt14, Ccdc108, Ngb, Gpx3, Gpr165, Nr2f2, Itih3, Pnoc), 48hWD and
astrocytes (3 – Trf, Kcnj5, F2rl2), and 48hWD and microglia (4 – Doc2g, Unc13c,
Plekhg3, Kif5a) experiments (Figure 3.7c). First, these data reveal nucleus
accumbal gene programs that are consistently driving or contributing to nicotine
withdrawal effects between 24 to 48 h withdrawal timeframe. In addition, these
data uncover a subset of genes that are differentially expressed both in nucleus
accumbens tissue and in either of the cell types evaluated at during nicotine
withdrawal.

3.5

DISCUSSION

Transcriptional programs are genomic regulatory code instructing the formation,
maintenance, and functions of diverse brain cell types and distinct brain structures.

81

Tissue- and cell type-specific evaluation of whole transcriptome can advance
current understanding of the role of genes in CNS health and disorders such as
nicotine dependence. In this study, we demonstrate that transcriptional programs
are temporally-regulated in the nucleus accumbens during chronic nicotine and
withdrawal. Additional investigation of transcriptome-wide responses to chronic
nicotine treatment and withdrawal at cell-type specific resolution shows that unlike
astrocytes, microglia are directly modulated by nicotine, resulting in myriad
changes in microglial gene expression. Our cell type-specific RNA-seq data further
show that during 48h withdrawal from nicotine, molecular pathways related to
metabolic processes are overrepresented in astrocytes while pathways associated
with inflammatory responses are overrepresented in microglia. Finally, during
nicotine withdrawal, we find subset of genes that are enriched in nucleus
accumbens tissue and either of the nucleus accumbens cell types examined.
Taken together, our study provides the first insight into cell type-specific and
tissue-level transcriptional remodeling in the nucleus accumbens in nicotine
dependence.

Temporal Transcriptional Changes in the Nucleus Accumbens during
Nicotine Withdrawal
Studies have shown that threshold levels of somatic signs and affective nicotine
withdrawal symptoms such as anxiety increase 24 h post nicotine administration
and completely wane by 96 h (Stoker et al 2008); however, transcriptional
mechanisms underlying the development and brief maintenance of these

82

behavioral symptoms are still unknown. First, in our differential gene expression
analysis data for saline versus nicotine, statistically significant enriched genes
were only found at 48hWD but not at 24hWD experiment. This is most likely due
to the variation in sequencing depth of our samples in both experiments since
nicotine treatment period was the same in both studies. Additionally, only 5 DEGs
were observed during nicotine treatment in the 48hWD experiment, suggesting
more sequencing depth is required in our 24hWD experiment to observe such a
small change. Lpl and Traip are part of the upregulated DEGs following nicotine
treatment. We found Lpl in overrepresented pathways related to lipid metabolism
and transport while Traip is associated with Tnfα-Nfkβ signaling pathway. It is
suggested that reduced Lpl levels may contribute to neurite pathology and reduced
neurogenesis potential in Alzheimer’s (Gong et al 2013) while Traip has been
shown to inhibit activation of Nfkβ mediated by Tnfα (Lee et al 1997). This suggest
upregulation of both genes during nicotine treatment may be neuroprotective.
Furthermore, our whole transcriptome studies show distinct gene programs in the
nucleus accumbens at 24 h and 48 h withdrawal timepoints. These findings
suggest that temporal transcriptional changes may underlie differential emergence
and diminishing thresholds of behavioral symptoms during the early periods of
nicotine withdrawal. However, further analyses show that a total (pairwise DGE
analysis between saline and withdrawal = 8 genes, and nicotine and withdrawal =
9 genes) of 14 unique enriched genes (Resp18, Sytl4, Ccdc108, Ngb, Gpx3,
Gpr165, Nr2f2, Itih3, Pnoc, Btg2, Syt17, Nr4a3, Slc6a11, Sparc) overlap between
DEGs at 24 h and 48 h withdrawal timepoints. These genes all have similar
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directionality (all upregulated) during 24 h and 48 h withdrawal, except for
Ccdc108, Syt17 and Nr4a3 that were upregulated at 24 h but downregulated at 48
h, and Btg2 that was consistently downregulated regardless of withdrawal period.
Interestingly, a number of these genes (Gpx3, Itih3, Ngb) have been shown to
respond to oxidative stress conditions (Herault et al 2012, Maes et al 2011, Wang
et al 2007, Watanabe et al 2012, Wickramasekara et al 2018), suggesting their
upregulation indicates oxidative imbalance during nicotine withdrawal. This is
further supported by increased Sparc expression, which is connected to elevation
of reactive oxygen species (ROS). Sparc gene deletion or deficiency have been
shown to have protective effect against oxidative stress (Aseer et al 2017, Peixoto
et al 2016). In addition, studies have shown that Btg2 is a coactivator for Nrf2 in
upregulating cellular antioxidant defenses (Karve & Rosen 2012); however, Btg2
was downregulated at 24 h and 48 h nicotine withdrawal timepoints. These findings
further suggest altered ROS homeostasis during nicotine withdrawal. One distinct
transcriptomic feature observed during 48 h withdrawal but not evident in 24 h
withdrawal is the enrichment of signaling pathways related to microglial proinflammatory cascades. Taken together, further studies may lead to transcriptomic
characterization of molecular events associated with behavioral symptomatology
in nicotine dependence.
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Transcriptome Remodeling in Microglia during Chronic Nicotine and
Withdrawal
Recently, microglia have emerged as central players in many brain disorders
(Salter & Stevens 2017), including drug addiction (Lewitus et al 2016b, Schwarz &
Bilbo 2013, Schwarz et al 2013); however, their role in nicotine dependence is
completely unknown. To study microglial transcriptomic changes in response to
chronic nicotine and withdrawal, we utilized cell type-specific RNA-seq. Our bulk
tissue RNA-seq studies capture RNAs from all cell types en masse; therefore,
transcriptomic composition of individual cell types is diluted and missed. First, our
data suggest that nicotine directly interacts with microglia, provoking myriad
transcriptome remodeling.
One of the notable changes is the upregulation of α4 and β2 nAChR subunits
following nicotine treatment. Further analysis revealed that both genes are part of
the nicotine addiction pathway, which is overrepresented in microglia. Our findings
show that α4β2 nAChR is upregulated in microglia in response to nicotine
treatment, suggesting a direct mechanism through which nicotine interacts with
microglia. Prior to this study, it is unclear whether or how nicotine interacts with
microglia. However, in contrast to our study, previous studies evaluating nicotine’s
effect on microglia using immortalized cell lines or primary microglial cultures have
reported the expression of homomeric α7-nAChR on microglia (De Simone et al
2005, King et al 2017, Mencel et al 2013, Shytle et al 2004, Suzuki et al 2006),
suggesting nicotine may directly interact with this receptor subtype on microglia to
elicit its effect. While these studies may have provided mechanistic insights into
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nicotine’s modulation of microglia, it is noteworthy that our approach, which
involves isolation and purification of microglia from fresh nucleus accumbens
tissue, presents microglia in a more natural state and provides better translatability
to in vivo situations. Another important consideration is the differences in brain
region from which microglia was prepared or isolated, as nAChR subtypes are
differentially expressed across brain regions. Furthermore, nicotine can also have
an indirect modulatory effect on microglia through enhancement of neuronmicroglia communication. One of the important bidirectional communication
between neurons and microglia is the interaction between fractalkine, Cx3cl1,
which is constitutively expressed in neurons and its receptor, Cx3cr1, which is
primarily expressed on microglia. Cx3cl1-Cx3cr1 signaling is required to keep
microglia in a surveying phenotype, and activation of Cx3cr1 provokes signal
cascades that modulates apoptotic, proliferative, transcriptional and migratory
functions in microglia (Szepesi et al 2018). However, our findings show that Cx3cr1
and other chemokines that could mediate neuron-microglia communication (Ccl2,
Ccl12, and CxCl9) were all downregulated following nicotine treatment, reinforcing
our previous findings. Furthermore, our data show that overrepresented pathways
including inflammatory responses, oxidative damage, toll-like receptor signaling,
macrophage markers, and microglia pathogen phagocytosis are downregulated in
microglia following nicotine treatment. These findings support previous studies that
have demonstrated nicotine’s neuroprotective property in neurodegenerative
disorders such as Alzheimer’s (Newhouse et al 2012, Wilson et al 1995) and
Parkinson’s (Villafane et al 2007), two disorders with extensive links to microglial
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activation and inflammatory responses (Amor et al 2010). However, during 48 h
nicotine withdrawal, enriched pathways such as inflammation mediated by
chemokine and cytokine signaling, toll-like receptor signaling, macrophage
markers are upregulated in microglia, suggesting nicotine withdrawal-induced
microglial pro-inflammatory signaling as well as microglia proliferation. Overall,
these data provide evidence for nicotine’s direct modulatory effect on microglia as
well as its suppression of microglial pro-inflammatory networks, which were all
activated during nicotine withdrawal.

Transcriptome Remodeling in Astrocytes during Chronic Nicotine and
Withdrawal
Astrocytes are actively involved in regulating the overall architecture and activity
of neuronal circuits (Szepesi et al 2018). While the role of astrocytes have been
studied in addiction to some drugs of abuse (Goins & Bajic 2018, Ikeda et al 2010,
Turner et al 2013a), their contributions in nicotine dependency is still unclear. We
found no enriched genes in astrocytes following nicotine treatment, suggesting that
nicotine does not have a direct modulatory effect on astrocytes. However, during
nicotine withdrawal, numerous genes were differentially expressed, suggesting
astrocyte

reactivity

to

withdrawal-related

insults

within

their

local

microenvironment. Further, our data show that overrepresented pathways
including biogenic amine synthesis, taurine and hypotaurine metabolism,
butanoate metabolism, beta-alanine metabolism and iron homeostasis are
upregulated in astrocytes, suggesting that astrocytes upregulate these metabolic
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pathways in response to withdrawal-related insults on neurons. Usually, astrocytes
optimize their metabolism to provide energy to the neurons that are deprived of
nutrients upon insult. These metabolic changes that astrocyte develop following
neuronal insult are one of the defining features of reactive astrocytes (Ben Haim
et al 2015, Iglesias et al 2017). Our data show that GAD1 and GAD2 (both
glutamate decarboxylases), which are both upregulated in our study, are involved
in many of the metabolic processes overrepresented in astrocytes during nicotine
withdrawal. GADs deplete glutamate levels in the brain to produce gamma
aminobutyric acid (GABA). Therefore, GAD upregulation may indicate alterations
in glutamate homeostasis and elevated GABA levels, which are both features
associated with reactive astrocyte (Ben Haim et al 2015). In fact, a study reported
that astrocytes can modulate microglia activity via GABA release (Lee et al 2011).
On the other hand, this supports the concept that astrocyte reactivity may be a
response to activated microglia, and not necessarily a direct response to neuronal
insult. Altogether, our astrocyte transcriptome data suggest that astrocyte undergo
transformation to the reactive phenotype, which may be a response to neuronal
insult or microglial activation during nicotine withdrawal.
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3.6

FIGURES

Figure 3.1. Differentially expressed genes in the nucleus accumbens during chronic
nicotine and withdrawal. a. Experimental design. b. Correlation matrix showing
relationships between withdrawal samples from 24hWD and 48hWD experiment. c.
Volcano plot showing statistically significant differentially expressed genes in i) 24hWD, ii)
48hWD experiments.
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Figure 3.2. Distinct gene programs are altered in the nucleus accumbens of mice in
the 24hWD and 48hWD experiments.
Heat map representation showing differentially expressed genes obtained from pairwise
DGE analysis of a. 24hWD experiment i) Sal (Saline) and 24 h withdrawal (24hWD), ii)
Nic (Nicotine) and 24 h withdrawal. b. 48hWD experiment i) Sal and Nic, ii) Sal and 48 h
withdrawal (48hWD), iii) Nic and 48 h withdrawal.

90

Figure 3.3. Overrepresented pathways in the nucleus accumbens during chronic
nicotine and withdrawal in the 24hWD and 48hWD experiments.
Pathway enrichment analysis highlighting some of the overrepresented pathways in a.
24hWD experiment i) Sal and 24 h withdrawal, ii) Nic and 24 h withdrawal. b. 48hWD
experiment i) Sal and Nic, ii) Sal and 48 h withdrawal, iii) Nic and 48 h withdrawal
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Figure 3.4. Evaluating the reproducibility of our data and conservation across
biological replicates. a. Bar graph showing quantitative PCR analysis of astrocytes
markers in the liver, brain cell-types and tissue (Total homogenate). i) Gfap, ii) S100b. b.
Correlation matrix showing relationships between nucleus accumbal Cd11b+ microglia and
ACSA II astrocytes samples. Sample clustering identify two potential outliers (in red-
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colored asterisks). c. Separate principal component analysis plot showing variation
between i) Cd11b+ microglia, ii) ACSA II astrocytes samples. Potential outlier samples
(same samples observed in 3.4b) are encircled by the red-colored ring. d. Correlation
matrix showing relationships between nucleus accumbal Cd11b+ microglia and ACSA II
astrocytes samples post-outlier removal. e. Heatmap showing the expression of classical
cell type markers in nucleus accumbal Cd11b+ microglia and ACSA II astrocytes samples
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Figure 3.5. Transcriptional programs in nucleus accumbal Cd11b+ microglia and
ACSA II astrocytes during chronic nicotine and 48 h withdrawal.
Heat map representation showing differentially expressed genes obtained from pairwise
DGE analysis of a. Cd11b+ microglia i) Sal and Nic, ii) Sal and 48 h withdrawal, iii) Nic and
48 h withdrawal. b. ACSA II astrocytes i) Sal and 48 h withdrawal, ii) Nic and 48 h
withdrawal.
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Figure 3.6. Overrepresented pathways in nucleus accumbal Cd11b+ microglia and
ACSA II astrocytes during chronic nicotine and 48 h withdrawal.
Pathway enrichment analysis showing some of the overrepresented pathways in a.
Cd11b+ microglia i) Sal and Nic, ii) Sal and 48 h withdrawal, iii) Nic and 48 h withdrawal.
b. ACSA II astrocytes i) Sal and 48 h withdrawal, ii) Nic and 48 h withdrawal.
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Figure 3.7. Graphical overview of unique and overlapping differentially expressed
gene in all RNA sequencing experiments.
Venn diagram showing relationships between differentially expressed genes in a. Sal and
Nic, b. Sal and Withdrawal, c. Nic and Withdrawal.
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CHAPTER 4
CONCLUSION
Neurons are the primary research target in the exploration and development of
novel smoking cessation pharmacotherapies. These investigations have led to the
discovery and development of three FDA-approved smoking cessation aids –
nicotine replacement therapy, varenicline, and bupropion, each of which elicit their
effects via modulation of neuronal function. However, while each of these
therapeutics have quantifiable success as smoking cessation aids, about 80% of
smokers attempting to quit still fail. This may be substantially due to inability of
these current aids to address some critical aspects of nicotine dependency.
Therefore, there is an urgent need to extend attention to non-neuronal cell types
such as astrocytes and microglia, which are both active participants in neuroplastic
events underlying drug addiction. This chapter will highlight the salient aspects of
this study and recommend experimental approaches to advance this project.

4.1

CHAPTER 2 SUMMARY

In Chapter 2, we conducted series of experiments that demonstrated a link
between oxidative stress signaling and nicotine withdrawal-related anxiety.
Neurons are particularly susceptible to oxidative stress insults, and it is thought
that these insults can activate neuronal signaling pathways that are associated
with the development of anxiety-like behavior during nicotine withdrawal. Our
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results showed that both pro-inflammatory signaling and oxidative stress during
nicotine withdrawal are limited to the nucleus accumbens, which has a critical role
in anxiety. Given that Nox system is the major source of intracellular ROS and
Nox2 subtype is primarily expressed in microglia, we hypothesized that oxidative
stress and nicotine withdrawal-related anxiety are direct consequences of
microglial morphological remodeling. Our findings provide the first evidence of
microglial involvement in nicotine dependence.

Future direction
While our molecular findings were based on the evaluation of striatum, our
behavioral data may result from molecular events within multiple neural substrates
of anxiety. Therefore, future studies may need to examine other neural substrates
of anxiety for the same molecular events (pro-inflammatory signaling, oxidative
stress, microglial morphological remodeling) observed in the nucleus accumbens
during nicotine withdrawal. Additional studies should also include region-specific
depletion of microglia or inhibition of microglia functions such as their proinflammatory signaling prior to behavioral and molecular assessments. Together,
this will elucidate brain regions that are actually associated with nicotinewithdrawal related anxiety.

4.2

CHAPTER 3 SUMMARY

Based on our findings in chapter 2, we extended our study to capture tissue-level
transcriptome changes in the nucleus accumbens during chronic nicotine and
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withdrawal (24 h and 48 h). This study uncovered temporal transcriptome changes
during the early stages of withdrawal (24 h to 48 h). Interestingly, we found a
substantial proportion of overlapping genes at these withdrawal timepoints to be
associated with dysregulation of ROS homeostasis and oxidative imbalance. This
corroborates our findings in chapter 2. More specifically, during 48 h withdrawal,
we found enrichment of gene subsets connected to microglia pro-inflammatory
signaling pathways.
To have a finer resolution that aid better characterization of transcriptomic
changes during chronic nicotine and withdrawal, we performed cell type-specific
RNA sequencing (RNA-seq) and evaluated astrocyte- and microglia-specific
transcriptome changes during chronic nicotine and 48 h withdrawal. In contrast to
previous suggestions of α7 nAChR on microglia, we identified α4β2 nAChR as the
potential receptor through which nicotine interacts directly with microglia. Chronic
nicotine

treatment

suppresses

pro-inflammatory

pathways

in

microglial

transcriptome while 48 h withdrawal activates them. This is consistent with many
studies assessing neuroinflammation in neurodegenerative disorders. For
astrocytes, we found that nicotine has no impact on their transcriptome; however,
during 48 h withdrawal, metabolic pathways in astrocytes are activated. Nicotine’s
activation of microglia but not astrocytes, and the type of responses from both cell
types during withdrawal present a consistent pattern with several studies that
demonstrated that activated microglia promotes reactive astrocytes in many
neurodegenerative diseases (Liu et al 2011).
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Compared to our nucleus accumbens tissue RNA-seq, astrocytes- and
microglia-specific RNA-seq gave us a less complex insight into the transcriptomic
changes observed at tissue-level during chronic nicotine and withdrawal.

Future direction
Future studies can include weighted correlation network analysis or weighted gene
co-expression network analysis (WGCNA) to determine clusters (modules) of
highly correlated genes in our enriched gene datasets (tissue and cell typespecific). Correlation networks aid network-based gene screening approaches that
can be used to determine candidate biomarkers or therapeutic targets. These
biomarkers or gene targets from WGCNA can then be validated using quantitative
PCR. Following validation, functional genomics studies should be performed to
study the function of these targets, as well as their impact on nicotine withdrawalrelevant behavioral phenotypes.
Finally, moving biomarkers or gene targets with therapeutic potential from
the laboratory to the point at which it is available as a medication is a long, rigorous
and expensive process. However, going forward, we do not doubt the
translatability of our findings given that certain modulators of microglia
differentiation and survival has already been developed and commercially
available.

100

REFERENCES
Allen NJ, Barres BA. 2009. Neuroscience: Glia — more than just brain glue. Nature
457: 675-77
Amor S, Puentes F, Baker D, van der Valk P. 2010. Inflammation in
neurodegenerative diseases. Immunology 129: 154-69
Aruoma OI, Halliwell B, Hoey BM, Butler J. 1989. The antioxidant action of Nacetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical,
superoxide, and hypochlorous acid. Free radical biology & medicine 6: 5937
Aseer KR, Silvester AJ, Kumar A, Choi MS, Yun JW. 2017. SPARC paucity
alleviates superoxide-mediated oxidative stress, apoptosis, and autophagy
in diabetogenic hepatocytes. Free radical biology & medicine 108: 874-95
Ashare RL, Falcone M, Lerman C. 2014. Cognitive function during nicotine
withdrawal:

Implications

for

nicotine

dependence

treatment.

Neuropharmacology 76 Pt B: 581-91
Babizhayev MA. 2014. The detox strategy in smoking comprising nutraceutical
formulas of non-hydrolyzed carnosine or carcinine used to protect human
health. Human & experimental toxicology 33: 284-316
Balfour DJK. 2008. The psychobiology of nicotine dependence. European
Respiratory Review 17: 172-

101

Barreto GE, Iarkov A, Moran VE. 2014. Beneficial effects of nicotine, cotinine and
its metabolites as potential agents for Parkinson's disease. Frontiers in
aging neuroscience 6: 340
Ben Haim L, Carrillo-de Sauvage MA, Ceyzeriat K, Escartin C. 2015. Elusive roles
for reactive astrocytes in neurodegenerative diseases. Frontiers in cellular
neuroscience 9: 278
Benowitz NL. 1999. Nicotine addiction. Prim Care 26: 611-31
Benowitz NL. 2008a. Clinical pharmacology of nicotine: implications for
understanding, preventing, and treating tobacco addiction. Clinical
pharmacology and therapeutics 83: 531-41
Benowitz NL. 2008b. Neurobiology of nicotine addiction: implications for smoking
cessation treatment. Am J Med 121: S3-10
Benowitz NL. 2010. Nicotine Addiction. New England Journal of Medicine 362:
2295-303
Bollinger JL, Bergeon Burns CM, Wellman CL. 2016. Differential effects of stress
on microglial cell activation in male and female medial prefrontal cortex.
Brain, behavior, and immunity 52: 88-97
Brunzell DH, Mineur YS, Neve RL, Picciotto MR. 2009. Nucleus accumbens CREB
activity

is

necessary

for

nicotine

conditioned

place

preference.

Neuropsychopharmacology : official publication of the American College of
Neuropsychopharmacology 34: 1993-2001

102

Brunzell DH, Russell DS, Picciotto MR. 2003. In vivo nicotine treatment regulates
mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. J
Neurochem 84: 1431-41
Buisson B, Bertrand D. 2001. Chronic exposure to nicotine upregulates the human
(alpha)4((beta)2 nicotinic acetylcholine receptor function. The Journal of
neuroscience : the official journal of the Society for Neuroscience 21: 181929
Buisson B, Bertrand D. 2002. Nicotine addiction: the possible role of functional
upregulation. Trends Pharmacol Sci 23: 130-6
Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, et al. 2014.
Identification of a unique TGF-β–dependent molecular and functional
signature in microglia. Nature neuroscience 17: 131-43
Butovsky O, Weiner HL. 2018. Microglial signatures and their role in health and
disease. Nat Rev Neurosci 19: 622-35
Cao L, Li L, Zuo Z. 2012. N-acetylcysteine reverses existing cognitive impairment
and increased oxidative stress in glutamate transporter type 3 deficient
mice. Neuroscience 220: 85-9
Cao Y-J, Surowy CS, Puttfarcken PS. 2005. Different nicotinic acetylcholine
receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine
release. Neuropharmacology 48: 72-79
Cerbai F, Lana D, Nosi D, Petkova-Kirova P, Zecchi S, et al. 2012. The neuronastrocyte-microglia triad in normal brain ageing and in a model of
neuroinflammation in the rat hippocampus. PloS one 7: e45250

103

Changeux J-P. 2010. Nicotine addiction and nicotinic receptors: lessons from
genetically modified mice. Nature Reviews Neuroscience 11: 389-401
Changeux JP, Devillers-Thiery A, Chemouilli P. 1984. Acetylcholine receptor: an
allosteric protein. Science 225: 1335-45
Chen WW, Zhang X, Huang WJ. 2016. Role of neuroinflammation in
neurodegenerative diseases (Review). Molecular medicine reports 13:
3391-6
Clarke R, Adermark L. 2015. Dopaminergic Regulation of Striatal Interneurons in
Reward and Addiction: Focus on Alcohol. Neural Plast 2015: 814567
Cleck JN, Ecke LE, Blendy JA. 2008. Endocrine and gene expression changes
following forced swim stress exposure during cocaine abstinence in mice.
Psychopharmacology 201: 15-28
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, et al. 2005. Varenicline:
an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
Journal of medicinal chemistry 48: 3474-7
Cohen A, Young RW, Velazquez MA, Groysman M, Noorbehesht K, et al. 2009.
Anxiolytic effects of nicotine in a rodent test of approach-avoidance conflict.
Psychopharmacology 204: 541-9
Cosci F. 2011. Nicotine dependence and psychological distress: outcomes and
clinical implications in smoking cessation. Psychology Research and
Behavior Management: 119
Cunningham C. 2013. Microglia and neurodegeneration: the role of systemic
inflammation. Glia 61: 71-90

104

D'Souza MS, Markou A. 2011. Neuronal mechanisms underlying development of
nicotine dependence: implications for novel smoking-cessation treatments.
Addict Sci Clin Pract 6: 4-16
D'Souza MS, Markou A. 2013. The "Stop" and "Go" of Nicotine Dependence: Role
of GABA and Glutamate. Cold Spring Harbor Perspectives in Medicine 3:
a012146-a46
Dani JA, De Biasi M. 2013. Mesolimbic Dopamine and Habenulo-Interpeduncular
Pathways in Nicotine Withdrawal. Cold Spring Harbor Perspectives in
Medicine 3: a012138-a38
Darsow T, Booker TK, Pina-Crespo JC, Heinemann SF. 2005. Exocytic trafficking
is required for nicotine-induced up-regulation of alpha 4 beta 2 nicotinic
acetylcholine receptors. The Journal of biological chemistry 280: 18311-20
Davis JA, James JR, Siegel SJ, Gould TJ. 2005. Withdrawal from chronic nicotine
administration impairs contextual fear conditioning in C57BL/6 mice. The
Journal of neuroscience : the official journal of the Society for Neuroscience
25: 8708-13
De Biase LM, Schuebel KE, Fusfeld ZH, Jair K, Hawes IA, et al. 2017. Local Cues
Establish and Maintain Region-Specific Phenotypes of Basal Ganglia
Microglia. Neuron 95: 341-56 e6
De Biasi M, Dani JA. 2011. Reward, addiction, withdrawal to nicotine. Annu Rev
Neurosci 34: 105-30
De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L. 2005. Activation of
alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates

105

cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J
Neuroinflammation 2: 4
Dekhuijzen PN. 2004. Antioxidant properties of N-acetylcysteine: their relevance
in relation to chronic obstructive pulmonary disease. The European
respiratory journal 23: 629-36
Ding X, Zhang M, Gu R, Xu G, Wu H. 2017. Activated microglia induce the
production of reactive oxygen species and promote apoptosis of co-cultured
retinal

microvascular

pericytes.

Graefe's

archive

for

clinical

and

experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und
experimentelle Ophthalmologie 255: 777-88
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, et al. 2013. STAR:
ultrafast universal RNA-seq aligner. Bioinformatics 29: 15-21
Dulawa SC, Hen R. 2005. Recent advances in animal models of chronic
antidepressant effects: the novelty-induced hypophagia test. Neurosci
Biobehav Rev 29: 771-83
Ernst M, Matochik JA, Heishman SJ, Van Horn JD, Jons PH, et al. 2001. Effect of
nicotine on brain activation during performance of a working memory task.
Proceedings of the National Academy of Sciences of the United States of
America 98: 4728-33
Ficklin MB, Zhao S, Feng G. 2005. Ubiquilin-1 regulates nicotine-induced upregulation of neuronal nicotinic acetylcholine receptors. The Journal of
biological chemistry 280: 34088-95

106

Fisher ML, LeMalefant RM, Zhou L, Huang G, Turner JR. 2017. Distinct Roles of
CREB Within the Ventral and Dorsal Hippocampus in Mediating Nicotine
Withdrawal Phenotypes. Neuropsychopharmacology : official publication of
the American College of Neuropsychopharmacology 42: 1599-609
Fowler CD, Arends MA, Kenny PJ. 2008. Subtypes of nicotinic acetylcholine
receptors in nicotine reward, dependence, and withdrawal: evidence from
genetically modified mice. Behav Pharmacol 19: 461-84
Fujiyama F, Sohn J, Nakano T, Furuta T, Nakamura KC, et al. 2011. Exclusive and
common targets of neostriatofugal projections of rat striosome neurons: a
single neuron-tracing study using a viral vector. Eur J Neurosci 33: 668-77
Galloway A, Adeluyi A, O'Donovan B, Fisher ML, Rao CN, et al. 2018. Dopamine
triggers CTCF-dependent morphological and genomic remodeling of
astrocytes. The Journal of Neuroscience: 3349-17
Gipson CD, Reissner KJ, Kupchik YM, Smith AC, Stankeviciute N, et al. 2013.
Reinstatement of nicotine seeking is mediated by glutamatergic plasticity.
Proceedings of the National Academy of Sciences of the United States of
America 110: 9124-9
Goins EC, Bajic D. 2018. Astrocytic hypertrophy in the rat ventral tegmental area
following chronic morphine differs with age. J Neurol Neurorehabilit Res 3:
14-21
Gong H, Dong W, Rostad SW, Marcovina SM, Albers JJ, et al. 2013. Lipoprotein
lipase (LPL) is associated with neurite pathology and its levels are markedly

107

reduced in the dentate gyrus of Alzheimer's disease brains. J Histochem
Cytochem 61: 857-68
Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, et al. 2006. Varenicline,
an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs
sustained-release bupropion and placebo for smoking cessation: a
randomized controlled trial. Jama 296: 47-55
Gotti C, Clementi F. 2004. Neuronal nicotinic receptors: from structure to
pathology. Prog Neurobiol 74: 363-96
Gould TJ, Portugal GS, Andre JM, Tadman MP, Marks MJ, et al. 2012. The
duration of nicotine withdrawal-associated deficits in contextual fear
conditioning parallels changes in hippocampal high affinity nicotinic
acetylcholine receptor upregulation. Neuropharmacology 62: 2118-25
Govind AP, Vezina P, Green WN. 2009. Nicotine-induced upregulation of nicotinic
receptors: underlying mechanisms and relevance to nicotine addiction.
Biochem Pharmacol 78: 756-65
Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, et al. 2007. The
subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of
mouse striatum. Biochemical Pharmacology 74: 1235-46
Graham AJ, Ray MA, Perry EK, Jaros E, Perry RH, et al. 2003. Differential nicotinic
acetylcholine receptor subunit expression in the human hippocampus. J
Chem Neuroanat 25: 97-113
Grunberg NE. 2007. A neurobiological basis for nicotine withdrawal. Proceedings
of the National Academy of Sciences 104: 17901-02

108

Guilarte TR, Loth MK, Guariglia SR. 2016. TSPO Finds NOX2 in Microglia for
Redox Homeostasis. Trends Pharmacol Sci 37: 334-43
Harada K, Kamiya T, Tsuboi T. 2015. Gliotransmitter Release from Astrocytes:
Functional, Developmental, and Pathological Implications in the Brain.
Front Neurosci 9: 499
Harkness PC, Millar NS. 2002. Changes in conformation and subcellular
distribution of alpha4beta2 nicotinic acetylcholine receptors revealed by
chronic nicotine treatment and expression of subunit chimeras. The Journal
of neuroscience : the official journal of the Society for Neuroscience 22:
10172-81
Herault O, Hope KJ, Deneault E, Mayotte N, Chagraoui J, et al. 2012. A role for
GPx3 in activity of normal and leukemia stem cells. J Exp Med 209: 895901
Huo Y, Rangarajan P, Ling EA, Dheen ST. 2011. Dexamethasone inhibits the Noxdependent ROS production via suppression of MKP-1-dependent MAPK
pathways in activated microglia. BMC neuroscience 12: 49
Hutchinson MR, Lewis SS, Coats BD, Skyba DA, Crysdale NY, et al. 2009.
Reduction of opioid withdrawal and potentiation of acute opioid analgesia
by systemic AV411 (ibudilast). Brain, behavior, and immunity 23: 240-50
Hyman SE, Malenka RC, Nestler EJ. 2006. NEURAL MECHANISMS OF
ADDICTION: The Role of Reward-Related Learning and Memory. Annual
Review of Neuroscience 29: 565-98

109

Iglesias J, Morales L, Barreto GE. 2017. Metabolic and Inflammatory Adaptation
of Reactive Astrocytes: Role of PPARs. Mol Neurobiol 54: 2518-38
Ikawa M, Okazawa H, Kudo T, Kuriyama M, Fujibayashi Y, Yoneda M. 2011.
Evaluation of striatal oxidative stress in patients with Parkinson's disease
using [62Cu]ATSM PET. Nuclear medicine and biology 38: 945-51
Ikeda H, Miyatake M, Koshikawa N, Ochiai K, Yamada K, et al. 2010. Morphine
modulation of thrombospondin levels in astrocytes and its implications for
neurite outgrowth and synapse formation. The Journal of biological
chemistry 285: 38415-27
Jackson KJ, Martin BR, Changeux JP, Damaj MI. 2008. Differential role of nicotinic
acetylcholine receptor subunits in physical and affective nicotine withdrawal
signs. The Journal of pharmacology and experimental therapeutics 325:
302-12
Jackson KJ, McIntosh JM, Brunzell DH, Sanjakdar SS, Damaj MI. 2009. The role
of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and
withdrawal. The Journal of pharmacology and experimental therapeutics
331: 547-54
Jiloha R. 2010. Biological basis of tobacco addiction: Implications for smokingcessation treatment. Indian Journal of Psychiatry 52: 301
Jiloha RC. 2014. Pharmacotherapy of smoking cessation. Indian J Psychiatry 56:
87-95
Karve TM, Rosen EM. 2012. B-cell translocation gene 2 (BTG2) stimulates cellular
antioxidant defenses through the antioxidant transcription factor NFE2L2 in

110

human mammary epithelial cells. The Journal of biological chemistry 287:
31503-14
Khakh BS, Sofroniew MV. 2015. Diversity of astrocyte functions and phenotypes
in neural circuits. Nature neuroscience 18: 942-52
Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, et al. 2011. Role of excitatory amino
acid

transporter-2

(EAAT2)

and

glutamate

in

neurodegeneration:

opportunities for developing novel therapeutics. J Cell Physiol 226: 248493
Kim KS, Lee KW, Baek IS, Lim CM, Krishnan V, et al. 2008. Adenylyl cyclase-5
activity in the nucleus accumbens regulates anxiety-related behavior. J
Neurochem 107: 105-15
King JR, Gillevet TC, Kabbani N. 2017. A G protein-coupled alpha7 nicotinic
receptor regulates signaling and TNF-alpha release in microglia. FEBS
Open Bio 7: 1350-61
Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, et al. 2009.
The role of cystine-glutamate exchange in nicotine dependence in rats and
humans. Biological psychiatry 65: 841-5
Koob G, Kreek MJ. 2007. Stress, dysregulation of drug reward pathways, and the
transition to drug dependence. Am J Psychiatry 164: 1149-59
Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, et al. 2016.
Enrichr: a comprehensive gene set enrichment analysis web server 2016
update. Nucleic acids research 44: W90-7

111

Kutlu MG, Gould TJ. 2016. Effects of drugs of abuse on hippocampal plasticity and
hippocampus-dependent

learning

and

memory:

contributions

to

development and maintenance of addiction. Learning & memory 23: 51533
Lee BG, Anastasia A, Hempstead BL, Lee FS, Blendy JA. 2015. Effects of the
BDNF Val66Met Polymorphism on Anxiety-Like Behavior Following
Nicotine Withdrawal in Mice. Nicotine & tobacco research : official journal
of the Society for Research on Nicotine and Tobacco 17: 1428-35
Lee M, Schwab C, McGeer PL. 2011. Astrocytes are GABAergic cells that
modulate microglial activity. Glia 59: 152-65
Lee SY, Lee SY, Choi Y. 1997. TRAF-interacting protein (TRIP): a novel
component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF
signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J
Exp Med 185: 1275-85
Leventhal AM, Ameringer KJ, Osborn E, Zvolensky MJ, Langdon KJ. 2013. Anxiety
and depressive symptoms and affective patterns of tobacco withdrawal.
Drug Alcohol Depend 133: 324-9
Leventhal AM, Strong DR, Kirkpatrick MG, Unger JB, Sussman S, et al. 2015.
Association of Electronic Cigarette Use With Initiation of Combustible
Tobacco Product Smoking in Early Adolescence. Jama 314: 700-7
Levita L, Hoskin R, Champi S. 2012. Avoidance of harm and anxiety: A role for the
nucleus accumbens. NeuroImage 62: 189-98

112

Lewitus GM, Konefal SC, Greenhalgh AD, Pribiag H, Augereau K, Stellwagen D.
2016a. Microglial TNF-alpha Suppresses Cocaine-Induced Plasticity and
Behavioral Sensitization. Neuron 90: 483-91
Lewitus Gil M, Konefal Sarah C, Greenhalgh Andrew D, Pribiag H, Augereau K,
Stellwagen D. 2016b. Microglial TNF-α Suppresses Cocaine-Induced
Plasticity and Behavioral Sensitization. Neuron 90: 483-91
Li G, Gong J, Lei H, Liu J, Xu XZS. 2016. Promotion of behavior and neuronal
function by reactive oxygen species in C. elegans. Nature Communications
7: 13234
Li Z, Ma L, Kulesskaya N, Voikar V, Tian L. 2014. Microglia are polarized to M1
type in high-anxiety inbred mice in response to lipopolysaccharide
challenge. Brain, behavior, and immunity 38: 237-48
Liao Y, Smyth GK, Shi W. 2014. featureCounts: an efficient general purpose
program for assigning sequence reads to genomic features. Bioinformatics
30: 923-30
Liu W, Tang Y, Feng J. 2011. Cross talk between activation of microglia and
astrocytes in pathological conditions in the central nervous system. Life Sci
89: 141-6
Liu Y, Zeng X, Hui Y, Zhu C, Wu J, et al. 2015. Activation of alpha7 nicotinic
acetylcholine receptors protects astrocytes against oxidative stress-induced
apoptosis: implications for Parkinson's disease. Neuropharmacology 91:
87-96

113

Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
25: 402-8
Lopez-Hidalgo M, Salgado-Puga K, Alvarado-Martinez R, Medina AC, PradoAlcala

RA,

Garcia-Colunga

J.

2012.

Nicotine

uses

neuron-glia

communication to enhance hippocampal synaptic transmission and longterm memory. PloS one 7: e49998
Lorberbaum JP, Kose S, Johnson MR, Arana GW, Sullivan LK, et al. 2004. Neural
correlates of speech anticipatory anxiety in generalized social phobia.
Neuroreport 15: 2701-5
Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and
dispersion for RNA-seq data with DESeq2. Genome Biol 15: 550
Lu JYD, Su P, Barber JEM, Nash JE, Le AD, et al. 2017. The neuroprotective effect
of nicotine in Parkinson's disease models is associated with inhibiting
PARP-1 and caspase-3 cleavage. PeerJ 5: e3933
Lull ME, Block ML. 2010. Microglial activation and chronic neurodegeneration.
Neurotherapeutics : the journal of the American Society for Experimental
NeuroTherapeutics 7: 354-65
Ma MW, Wang J, Zhang Q, Wang R, Dhandapani KM, et al. 2017. NADPH oxidase
in

brain

injury

and

neurodegenerative

disorders.

Molecular

Neurodegeneration 12
Madore C, Baufeld C, Butovsky O. 2017. Microglial confetti party. Nature
neuroscience 20: 762-63

114

Madsen HB, Brown RM, Lawrence AJ. 2012. Neuroplasticity in addiction: cellular
and transcriptional perspectives. Front Mol Neurosci 5: 99
Maes M, Galecki P, Chang YS, Berk M. 2011. A review on the oxidative and
nitrosative stress (O&NS) pathways in major depression and their possible
contribution to the (neuro)degenerative processes in that illness. Prog
Neuropsychopharmacol Biol Psychiatry 35: 676-92
Manhaes AC, Guthierrez MC, Filgueiras CC, Abreu-Villaca Y. 2008. Anxiety-like
behavior

during

nicotine

withdrawal

predict

subsequent

nicotine

consumption in adolescent C57BL/6 mice. Behavioural brain research 193:
216-24
Markou

A.

2008.

Neurobiology

of

nicotine

dependence.

Philosophical

Transactions of the Royal Society B: Biological Sciences 363: 3159-68
Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, et al. 2007.
Guidelines

on

nicotine

dose

selection

for

in

vivo

research.

Psychopharmacology 190: 269-319
McCarthy MM. 2017. Location, Location, Location: Microglia Are Where They Live.
Neuron 95: 233-35
McLaughlin I, Dani JA, De Biasi M. 2015. Nicotine Withdrawal

In The

Neuropharmacology of Nicotine Dependence, ed. DJK Balfour, MR Munafò,
pp. 99-123. Cham: Springer International Publishing
Mencel M, Nash M, Jacobson C. 2013. Neuregulin upregulates microglial alpha7
nicotinic acetylcholine receptor expression in immortalized cell lines:
implications for regulating neuroinflammation. PloS one 8: e70338

115

Miyamoto A, Wake H, Ishikawa AW, Eto K, Shibata K, et al. 2016. Microglia contact
induces synapse formation in developing somatosensory cortex. Nat
Commun 7: 12540
Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff RM, Cardona AE. 2012.
The fractalkine receptor but not CCR2 is present on microglia from
embryonic development throughout adulthood. Journal of immunology 188:
29-36
Morganti JM, Jopson TD, Liu S, Riparip LK, Guandique CK, et al. 2015. CCR2
antagonism alters brain macrophage polarization and ameliorates cognitive
dysfunction induced by traumatic brain injury. The Journal of neuroscience
: the official journal of the Society for Neuroscience 35: 748-60
Morud J, Strandberg J, Andren A, Ericson M, Soderpalm B, Adermark L. 2018.
Progressive modulation of accumbal neurotransmission and anxiety-like
behavior following protracted nicotine withdrawal. Neuropharmacology 128:
86-95
Nayernia Z, Jaquet V, Krause KH. 2014. New insights on NOX enzymes in the
central nervous system. Antioxidants & redox signaling 20: 2815-37
Nestler EJ. 2008. Review. Transcriptional mechanisms of addiction: role of
DeltaFosB. Philos Trans R Soc Lond B Biol Sci 363: 3245-55
Newhouse P, Kellar K, Aisen P, White H, Wesnes K, et al. 2012. Nicotine treatment
of mild cognitive impairment: a 6-month double-blind pilot clinical trial.
Neurology 78: 91-101

116

Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, et al. 2014.
Smoking Prevalence and Cigarette Consumption in 187 Countries, 19802012. Jama 311: 183
Orient A, Donko A, Szabo A, Leto TL, Geiszt M. 2007. Novel sources of reactive
oxygen species in the human body. Nephrology, dialysis, transplantation :
official publication of the European Dialysis and Transplant Association European Renal Association 22: 1281-8
Panday A, Sahoo MK, Osorio D, Batra S. 2015. NADPH oxidases: an overview
from structure to innate immunity-associated pathologies. Cellular &
molecular immunology 12: 5-23
Pang X, Liu L, Ngolab J, Zhao-Shea R, McIntosh JM, et al. 2016. Habenula
cholinergic neurons regulate anxiety during nicotine withdrawal via nicotinic
acetylcholine receptors. Neuropharmacology 107: 294-304
Parikh V, Cole RD, Patel PJ, Poole RL, Gould TJ. 2016. Cognitive control deficits
during mecamylamine-precipitated withdrawal in mice: Possible links to
frontostriatal BDNF imbalance. Neurobiology of learning and memory 128:
110-6
Patki G, Solanki N, Atrooz F, Allam F, Salim S. 2013. Depression, anxiety-like
behavior and memory impairment are associated with increased oxidative
stress and inflammation in a rat model of social stress. Brain research 1539:
73-86

117

Patterson F, Jepson C, Strasser AA, Loughead J, Perkins KA, et al. 2009.
Varenicline improves mood and cognition during smoking abstinence.
Biological psychiatry 65: 144-9
Peixoto A, Fernandes E, Gaiteiro C, Lima L, Azevedo R, et al. 2016. Hypoxia
enhances the malignant nature of bladder cancer cells and concomitantly
antagonizes protein O-glycosylation extension. Oncotarget 7: 63138-57
Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J. 1994. Nicotine-induced
increase in neuronal nicotinic receptors results from a decrease in the rate
of receptor turnover. Molecular pharmacology 46: 523-30
Perry VH, Nicoll JA, Holmes C. 2010. Microglia in neurodegenerative disease.
Nature reviews. Neurology 6: 193-201
Picciotto MR, Addy NA, Mineur YS, Brunzell DH. 2008. It is not "either/or":
activation and desensitization of nicotinic acetylcholine receptors both
contribute to behaviors related to nicotine addiction and mood. Prog
Neurobiol 84: 329-42
Piper ME, Cook JW, Schlam TR, Jorenby DE, Baker TB. 2011. Anxiety diagnoses
in

smokers

seeking

cessation

treatment:

relations

with

tobacco

dependence, withdrawal, outcome and response to treatment. Addiction
106: 418-27
Polosa R, Benowitz NL. 2011. Treatment of nicotine addiction: present therapeutic
options and pipeline developments. Trends Pharmacol Sci 32: 281-9

118

Portugal GS, Gould TJ. 2007. Bupropion dose-dependently reverses nicotine
withdrawal deficits in contextual fear conditioning. Pharmacology,
biochemistry, and behavior 88: 179-87
Portugal GS, Kenney JW, Gould TJ. 2008. Beta2 subunit containing acetylcholine
receptors mediate nicotine withdrawal deficits in the acquisition of
contextual fear conditioning. Neurobiology of learning and memory 89: 10613
Portugal GS, Wilkinson DS, Turner JR, Blendy JA, Gould TJ. 2012. Developmental
effects of acute, chronic, and withdrawal from chronic nicotine on fear
conditioning. Neurobiology of learning and memory 97: 482-94
Primack BA, Soneji S, Stoolmiller M, Fine MJ, Sargent JD. 2015. Progression to
Traditional Cigarette Smoking After Electronic Cigarette Use Among US
Adolescents and Young Adults. JAMA pediatrics 169: 1018-23
Prinz M, Priller J. 2010. Tickets to the brain: role of CCR2 and CX3CR1 in myeloid
cell entry in the CNS. J Neuroimmunol 224: 80-4
Prochaska JJ, Benowitz NL. 2016. The Past, Present, and Future of Nicotine
Addiction Therapy. Annual Review of Medicine 67: 467-86
Qin L, Liu Y, Wang T, Wei SJ, Block ML, et al. 2004. NADPH oxidase mediates
lipopolysaccharide-induced

neurotoxicity

and

proinflammatory

gene

expression in activated microglia. The Journal of biological chemistry 279:
1415-21

119

Quik M, Huang LZ, Parameswaran N, Bordia T, Campos C, Perez XA. 2009.
Multiple roles for nicotine in Parkinson's disease. Biochem Pharmacol 78:
677-85
Ransohoff RM. 2016. A polarizing question: do M1 and M2 microglia exist? Nature
neuroscience 19: 987-91
Rastogi R, Geng X, Li F, Ding Y. 2016. NOX Activation by Subunit Interaction and
Underlying Mechanisms in Disease. Frontiers in cellular neuroscience 10:
301
Reitsma MB, Fullman N, Ng M, Salama JS, Abajobir A, et al. 2017. Smoking
prevalence and attributable disease burden in 195 countries and territories,
1990–2015: a systematic analysis from the Global Burden of Disease Study
2015. The Lancet 389: 1885-906
Rezvani K, Teng Y, Shim D, De Biasi M. 2007. Nicotine regulates multiple synaptic
proteins by inhibiting proteasomal activity. The Journal of neuroscience :
the official journal of the Society for Neuroscience 27: 10508-19
Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, et al. 2007.
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor
partial

agonist

varenicline,

an

effective

smoking

cessation

aid.

Neuropharmacology 52: 985-94
Ross GW, Petrovitch H. 2001. Current evidence for neuroprotective effects of
nicotine and caffeine against Parkinson's disease. Drugs & aging 18: 797806

120

Russo SJ, Nestler EJ. 2013. The brain reward circuitry in mood disorders. Nature
Reviews Neuroscience 14: 609-25
Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, et al. 2010. Selective
chemokine receptor usage by central nervous system myeloid cells in
CCR2-red fluorescent protein knock-in mice. PloS one 5: e13693
Salim S, Sarraj N, Taneja M, Saha K, Tejada-Simon MV, Chugh G. 2010.
Moderate treadmill exercise prevents oxidative stress-induced anxiety-like
behavior in rats. Behavioural brain research 208: 545-52
Sallette J, Pons S, Devillers-Thiery A, Soudant M, Prado de Carvalho L, et al. 2005.
Nicotine upregulates its own receptors through enhanced intracellular
maturation. Neuron 46: 595-607
Salter MW, Stevens B. 2017. Microglia emerge as central players in brain disease.
Nature medicine 23: 1018-27
Samet JM. 2013. Tobacco smoking: the leading cause of preventable disease
worldwide. Thoracic surgery clinics 23: 103-12
Saravia R, Ten-Blanco M, Grande MT, Maldonado R, Berrendero F. 2019. Antiinflammatory agents for smoking cessation? Focus on cognitive deficits
associated with nicotine withdrawal in male mice. Brain, behavior, and
immunity 75: 228-39
Schieber M, Chandel NS. 2014. ROS function in redox signaling and oxidative
stress. Current biology : CB 24: R453-62
Schwarz JM, Bilbo SD. 2013. Adolescent morphine exposure affects long-term
microglial function and later-life relapse liability in a model of addiction. The

121

Journal of neuroscience : the official journal of the Society for Neuroscience
33: 961-71
Schwarz JM, Smith SH, Bilbo SD. 2013. FACS analysis of neuronal–glial
interactions in the nucleus accumbens following morphine administration.
Psychopharmacology 230: 525-35
Seo JS, Park JY, Choi J, Kim TK, Shin JH, et al. 2012. NADPH oxidase mediates
depressive behavior induced by chronic stress in mice. The Journal of
neuroscience : the official journal of the Society for Neuroscience 32: 96909
Sharma G, Vijayaraghavan S. 2001. Nicotinic cholinergic signaling in hippocampal
astrocytes involves calcium-induced calcium release from intracellular
stores. Proceedings of the National Academy of Sciences of the United
States of America 98: 4148-53
Sharples CGV, Kaiser S, Soliakov L, Marks MJ, Collins AC, et al. 2000. UB-165:
A Novel Nicotinic Agonist with Subtype Selectivity Implicates the α4β2*
Subtype in the Modulation of Dopamine Release from Rat Striatal
Synaptosomes. The Journal of Neuroscience 20: 2783-91
Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, et al. 2004. Cholinergic
modulation of microglial activation by alpha 7 nicotinic receptors. J
Neurochem 89: 337-43
Sidiropoulos K, Viteri G, Sevilla C, Jupe S, Webber M, et al. 2017. Reactome
enhanced pathway visualization. Bioinformatics 33: 3461-67

122

Sofroniew MV, Vinters HV. 2010. Astrocytes: biology and pathology. Acta
Neuropathologica 119: 7-35
Spencer S, Kalivas PW. 2017. Glutamate Transport: A New Bench to Bedside
Mechanism for Treating Drug Abuse. Int J Neuropsychopharmacol 20: 797812
Stansley B, Post J, Hensley K. 2012. A comparative review of cell culture systems
for

the

study

of

microglial

biology

in

Alzheimer's

disease.

J

Neuroinflammation 9: 115
Stein DJ, Vasconcelos MF, Albrechet-Souza L, Cereser KMM, de Almeida RMM.
2017. Microglial Over-Activation by Social Defeat Stress Contributes to
Anxiety- and Depressive-Like Behaviors. Front Behav Neurosci 11: 207
Stoker AK, Semenova S, Markou A. 2008. Affective and somatic aspects of
spontaneous and precipitated nicotine withdrawal in C57BL/6J and
BALB/cByJ mice. Neuropharmacology 54: 1223-32
Streit WJ. 2002. Microglia as neuroprotective, immunocompetent cells of the CNS.
Glia 40: 133-9
Sun SY. 2010. N-acetylcysteine, reactive oxygen species and beyond. Cancer
biology & therapy 9: 109-10
Suzuki H, Sugimura Y, Iwama S, Suzuki H, Nobuaki O, et al. 2010a. Minocycline
prevents osmotic demyelination syndrome by inhibiting the activation of
microglia. Journal of the American Society of Nephrology : JASN 21: 20908

123

Suzuki T, Hide I, Matsubara A, Hama C, Harada K, et al. 2006. Microglial alpha7
nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and
modulate the cell activation toward a neuroprotective role. J Neurosci Res
83: 1461-70
Suzuki YJ, Carini M, Butterfield DA. 2010b. Protein carbonylation. Antioxidants &
redox signaling 12: 323-5
Szepesi Z, Manouchehrian O, Bachiller S, Deierborg T. 2018. Bidirectional
Microglia-Neuron Communication in Health and Disease. Frontiers in
cellular neuroscience 12: 323
Tang Y, Le W. 2016. Differential Roles of M1 and M2 Microglia in
Neurodegenerative Diseases. Mol Neurobiol 53: 1181-94
Tariq M, Khan HA, Elfaki I, Al Deeb S, Al Moutaery K. 2005. Neuroprotective effect
of nicotine against 3-nitropropionic acid (3-NP)-induced experimental
Huntington's disease in rats. Brain research bulletin 67: 161-8
Teaktong T, Graham A, Court J, Perry R, Jaros E, et al. 2003. Alzheimer's disease
is associated with a selective increase in alpha7 nicotinic acetylcholine
receptor immunoreactivity in astrocytes. Glia 41: 207-11
Torregrossa MM, Corlett PR, Taylor JR. 2011. Aberrant learning and memory in
addiction. Neurobiology of learning and memory 96: 609-23
Torres L, Danver J, Ji K, Miyauchi JT, Chen D, et al. 2016. Dynamic microglial
modulation of spatial learning and social behavior. Brain, behavior, and
immunity 55: 6-16

124

Torres OV, Pipkin JA, Ferree P, Carcoba LM, O'Dell LE. 2015. Nicotine withdrawal
increases stress-associated genes in the nucleus accumbens of female rats
in a hormone-dependent manner. Nicotine & tobacco research : official
journal of the Society for Research on Nicotine and Tobacco 17: 422-30
Tumkosit P, Kuryatov A, Luo J, Lindstrom J. 2006. Beta3 subunits promote
expression and nicotine-induced up-regulation of human nicotinic alpha6*
nicotinic acetylcholine receptors expressed in transfected cell lines.
Molecular pharmacology 70: 1358-68
Turner JR, Ecke LE, Briand LA, Haydon PG, Blendy JA. 2013a. Cocaine-related
behaviors in mice with deficient gliotransmission. Psychopharmacology
226: 167-76
Turner JR, Ray R, Lee B, Everett L, Xiang J, et al. 2014. Evidence from mouse
and man for a role of neuregulin 3 in nicotine dependence. Mol Psychiatry
19: 801-10
Turner JR, Wilkinson DS, Poole RLF, Gould TJ, Carlson GC, Blendy JA. 2013b.
Divergent Functional Effects of Sazetidine-A and Varenicline During
Nicotine Withdrawal. Neuropsychopharmacology : official publication of the
American College of Neuropsychopharmacology 38: 2035-47
van der Kooij MA, Hollis F, Lozano L, Zalachoras I, Abad S, et al. 2018. Diazepam
actions in the VTA enhance social dominance and mitochondrial function in
the nucleus accumbens by activation of dopamine D1 receptors. Molecular
Psychiatry 23: 569-78

125

Victor VM, Rocha M, De la Fuente M. 2003. Regulation of macrophage function by
the antioxidant N-acetylcysteine in mouse-oxidative stress by endotoxin.
International immunopharmacology 3: 97-106
Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, et al. 2007. Chronic high dose
transdermal nicotine in Parkinson's disease: an open trial. European journal
of neurology 14: 1313-6
Volkow ND, Li T-K. 2004. Science and Society: Drug addiction: the neurobiology
of behaviour gone awry. Nature Reviews Neuroscience 5: 963-70
Volkow Nora D, Morales M. 2015. The Brain on Drugs: From Reward to Addiction.
Cell 162: 712-25
Wang X, Pal R, Chen XW, Kumar KN, Kim OJ, Michaelis EK. 2007. Genome-wide
transcriptome profiling of region-specific vulnerability to oxidative stress in
the hippocampus. Genomics 90: 201-12
Wang YL, Han QQ, Gong WQ, Pan DH, Wang LZ, et al. 2018. Microglial activation
mediates chronic mild stress-induced depressive- and anxiety-like behavior
in adult rats. J Neuroinflammation 15: 21
Watanabe S, Takahashi N, Uchida H, Wakasugi K. 2012. Human neuroglobin
functions as an oxidative stress-responsive sensor for neuroprotection. The
Journal of biological chemistry 287: 30128-38
Weinhard L, di Bartolomei G, Bolasco G, Machado P, Schieber NL, et al. 2018.
Microglia remodel synapses by presynaptic trogocytosis and spine head
filopodia induction. Nat Commun 9: 1228

126

Whiting PJ, Lindstrom JM. 1988. Characterization of bovine and human neuronal
nicotinic acetylcholine receptors using monoclonal antibodies. The Journal
of neuroscience : the official journal of the Society for Neuroscience 8: 3395404
Wickramasekara RN, Morrill S, Farhat Y, Smith SJ, Yilmazer-Hanke D. 2018.
Glutathione and Inter-alpha-trypsin inhibitor heavy chain 3 (Itih3) mRNA
levels in nicotine-treated Cd44 knockout mice. Toxicol Rep 5: 759-64
Wilson AL, Langley LK, Monley J, Bauer T, Rottunda S, et al. 1995. Nicotine
patches in Alzheimer's disease: pilot study on learning, memory, and safety.
Pharmacology, biochemistry, and behavior 51: 509-14
Wonnacott S. 1990. The paradox of nicotinic acetylcholine receptor upregulation
by nicotine. Trends Pharmacol Sci 11: 216-9
World Health Organization. 2012. WHO global report: mortality attributable to
tobacco.Geneva,Switzerland.
http://apps.who.int/iris/bitstream/10665/44815/1/9789241564434_eng.pdf.
Xiao C, Nashmi R, McKinney S, Cai H, McIntosh JM, Lester HA. 2009. Chronic
Nicotine Selectively Enhances 4 2* Nicotinic Acetylcholine Receptors in the
Nigrostriatal Dopamine Pathway. Journal of Neuroscience 29: 12428-39
Xiao Y, Fan H, Musachio JL, Wei ZL, Chellappan SK, et al. 2006. Sazetidine-A, a
novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors
without activating them. Molecular pharmacology 70: 1454-60
Yager LM, Garcia AF, Wunsch AM, Ferguson SM. 2015. The ins and outs of the
striatum: role in drug addiction. Neuroscience 301: 529-41

127

Yohn NL, Turner JR, Blendy JA. 2014. Activation of alpha4beta2*/alpha6beta2*
nicotinic receptors alleviates anxiety during nicotine withdrawal without
upregulating nicotinic receptors. The Journal of pharmacology and
experimental therapeutics 349: 348-54
Zhang T, Zhang L, Liang Y, Siapas AG, Zhou FM, Dani JA. 2009. Dopamine
Signaling Differences in the Nucleus Accumbens and Dorsal Striatum
Exploited by Nicotine. Journal of Neuroscience 29: 4035-43
Zhang W, Xiao S, Ahn DU. 2013. Protein oxidation: basic principles and
implications for meat quality. Critical reviews in food science and nutrition
53: 1191-201
Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, et al. 2014. An RNAsequencing transcriptome and splicing database of glia, neurons, and
vascular cells of the cerebral cortex. The Journal of neuroscience : the
official journal of the Society for Neuroscience 34: 11929-47
Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, et al. 2016. Purification and
Characterization of Progenitor and Mature Human Astrocytes Reveals
Transcriptional and Functional Differences with Mouse. Neuron 89: 37-53
Zhu F, Zheng Y, Ding YQ, Liu Y, Zhang X, et al. 2014. Minocycline and risperidone
prevent microglia activation and rescue behavioral deficits induced by
neonatal intrahippocampal injection of lipopolysaccharide in rats. PloS one
9: e93966
Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C. 2002. Identification
of the nicotinic receptor subtypes expressed on dopaminergic terminals in

128

the rat striatum. The Journal of neuroscience : the official journal of the
Society for Neuroscience 22: 8785

129

APPENDIX A
CODE FOR RNA SEQUENCING ANALYSIS
################################################################
#################RNA-Seq Data Analysis Pipeline on UNIX #############
#mm10 genome was downloaded from iGenomes
#https://support.illumina.com/sequencing/sequencing_software/igenome.html

#Generating genome indexes
module load gcc/4.9.1
module load star/2.5

STAR --runThreadN 20 --runMode genomeGenerate --genomeDir
/work/adeluyi/mm10genome_indexes --genomeFastaFiles
/work/adeluyi/mm10genome/mm10genome.fa --sjdbGTFfile
/work/adeluyi/mm10genome/mm10genes.gtf --sjdbOverhang 75

#Checking read quality using FastQC
module load fastqc/0.11.5

for i in /work/adeluyi/input_folder/cat_files/*fastq.gz;
do fastqc --outdir /work/adeluyi/output_folder/fq_files -t 10 $i;
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done

#For reads that need adapter trimming
module load bbmap/gcc/38.16

for i in `ls -1 /work/adeluyi/input_folder/ fastq_file/*_1.fastq.gz | sed
's/_1.fastq.gz//'`
do bbduk.sh in1=$i\_1.fastq.gz in2=$i\_2.fastq.gz
out1=$i\_clean_1.fastq.gz out2=$i\_clean_2.fastq.gz ktrim=r k=21
literal=GATCGGAAGAGCACACGTCTGAACTCCAGTCACTGATCACGATCTCG
TATGCCGTCTTCTGCTTGAAAAAAAAAA,GATCGGAAGAGCGTCGTGTAGGG
AAAGAGTGTCGTGATCAGTGTAGATCTCGGTGGTCGCCGTATCATTAAAAAA
,ATCGGAAGAGCACACGTCTGAACTCCAGTCACCCACATTGATCTCGTATGC
CGTCTTCTGCTTGAAAAAAAAAAA,ATCGGAAGAGCGTCGTGTAGGGAAAGA
GTGTCAATGTGGGTGTAGATCTCGGTGGTCGCCGTATCATTAAAAAAA,AAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAA,TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT tbo tpe
done

#Mapping reads to genome
module load gcc/4.9.1
module load star/2.5
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for i in $(ls /work/adeluyi/input folder/cat_files | sed s/_[12].fastq.gz// | sort -u);

do STAR --genomeDir /work/adeluyi/mm10genome_indexes --readFilesIn
/work/adeluyi/input folder/cat_files/${i}_1.fastq.gz
/work/adeluyi/input_folder/cat_files/${i}_2.fastq.gz
--runThreadN 20 --outFileNamePrefix
/work/adeluyi/output_folder/mapped_reads/$i.
--sjdbGTFfile /work/adeluyi/mm10genome/mm10genes.gtf
--sjdbOverhang 75 --readFilesCommand zcat;
done

#Read count and summarization
module load subread/1.5.3

featureCounts -p -s 2 -t exon -g gene_id -a
/work/adeluyi/mm10genome/mm10genes.gtf -o
/work/adeluyi/output_folder/count_files/ count.txt
/work/adeluyi/input_folder/mapped_reads/*Aligned.out.sam*
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################################################################
################ Statistical Data Analysis on R Software#################
#For this part, I am using the analysis of NAc48hWD experiment as an example.
Other

experiments

(NAc24hWD,

Microglia-specific

and

Astrocyte-specific

experiments) were passed through the same analysis pipeline.

NAc = read.csv("NAc48hWD_count.csv", header = T)
head(NAc)

####### Filter out low read counts
lowread = apply(NAc,1,max)
whcount = which(lowread<5)
length(whcount)
NAc_data = NAc[-whcount,]
dim(NAc_data)
rownames(NAc_data) = NAc_data$Geneid
head(NAc_data)
NAc_data = NAc_data[,-1]
head(NAc_data)
NAc_data1=data.frame(Gene=rownames(NAc_data),Sal1=NAc_data$Sal1,Sal2
=NAc_data$Sal2,Sal3=NAc_data$Sal3,Sal4=NAc_data$Sal4,Nic1=NAc_data$Ni
c5,Nic2=NAc_data$Nic6,Nic3=NAc_data$Nic7,WD1=NAc_data$WD8,WD2=NAc
_data$WD9,WD3=NAc_data$WD10)
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rownames(NAc_data1) = NAc_data1$Gene
head(NAc_data1)
NAc_data1 = NAc_data1[,-1]
head(NAc_data1)
Nlen = as.vector(NAc_data$Length)

########## Differential Expression Analysis
NAc_col= read.csv("NAc_metadata.csv",header = T)
head(NAc_col)
NAc_col=data.frame(Sample=NAc_col$Sample,Treatment= NAc_col$Treatment)

BiocManager::install(c("DESeq2","GenomicFeatures", "AnnotationDbi"))
BiocManager::install(c("rtracklayer","GenomicAlignments", "Rsamtools"))
library("DESeq2")
library("AnnotationDbi")
library("GenomicFeatures")
library("rtracklayer")
library("Rsamtools")
library("GenomicAlignments")

NAc_dds = DESeqDataSetFromMatrix(NAc_data1,NAc_col,~Treatment)
NAc_dds1<-DESeq(NAc_dds)
res_NAc<-results(NAc_dds1)
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head(res_NAc)

plotMA(res_NAc, main="MA Plot with DESeq2: 48hWD Nicotine Studies")
tsig_NAc = table(res_NAc[,6]<0.2)
tsig_res_NAc = which(res_NAc[,6]<0.2)
sig_NAc = res_NAc[tsig_res_NAc,]
head(sig_NAc)
rownames(sig_NAc)

sig_ordNAc = sig_NAc[order(sig_NAc$log2FoldChange,decreasing = TRUE),]
head(sig_ordNAc)
DEG=data.frame(Gene=rownames(sig_ordNAc),log2FC=sig_ordNAc$log2FoldC
hange,pvalue=sig_ordNAc$pvalue,padj=sig_ordNAc$padj)
row.names(DEG)<- NULL
write.csv(DEG,"NAc_DEG(48hWD).csv", row.names = FALSE)
NAc48hWD_cutoff = DEG[DEG$log2FC>0.5|DEG$log2FC < -0.5,]
write.csv(NAc48hWD_cutoff,"NAc48hWD_cutoff.csv", row.names = FALSE)

############ PCA plot
N_rld <- rlog(NAc_dds1, blind=FALSE)
plotPCA(N_rld, intgroup=c("Sample", "Treatment"))
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############ Volcano plot
install.packages("ggrepel")
library("ggrepel")
install.packages("plyr")
library("plyr")
library("dplyr")

# Cutoff for differential expression
fc = 0.5
cf = -0.5
pval = 0.2

DEG1=data.frame(Gene=rownames(sig_ordNAc),log2FC=(1*sig_ordNAc$log2F
oldChange),pvalue=sig_ordNAc$pvalue,qvalue=sig_ordNAc$padj)
head(DEG1)
Ntex=c("Nr4a3","C4b","Cybb","Sparc","Malat1","Chat","Adamts14","Dusp4","Ada
mts8","Stard8","CD38","Stat4","Gpr165","Mef2c","Slc6a11","Hck","Egln3","Itih3")
N_genes = DEG1[DEG1$Gene %in% Ntex,]
N_res=data.frame(Gene=rownames(res_NAc),log2FC=(1*res_NAc$log2FoldCha
nge),pvalue=res_NAc$pvalue,qvalue=res_NAc$padj)
head(N_res)
Nlog_res=data.frame(log2FC=(-1*res_NAc$log2FoldChange),neglogP=log10(res_NAc$pvalue),neglogFDR=-log10(res_NAc$padj))
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rownames(Nlog_res) = rownames(res_NAc)
head(Nlog_res)

N_resmut=mutate(N_res,Expression=ifelse(Nlog_res$log2FC>fc&
Nlog_res$neglogFDR> -log10(pval), "Upregulated", ifelse(Nlog_res$log2FC<cf &
Nlog_res$neglogFDR> -log10(pval),"Downregulated”,” Not significant")))
table(N_resmut$Expression)
head(N_resmut)
volc=ggplot(na.omit(N_resmut))

+

aes(x=log2FC,

y=-log10(qvalue))

+

geom_point(aes(color = Expression),alpha=0.65) +
scale_color_manual(values = c("blue","grey40","firebrick3")) + xlim(c(-6.5, 6)) +
ylim(c(0,5)) +
ggtitle("VOLCANO PLOT","Differentially Expressed Genes")+
geom_vline(xintercept = c(-0.5,0.5), colour = "grey30") +
geom_hline(yintercept = 0.69, colour = "grey30") +
theme(plot.background = element_rect(), panel.grid.major=element_blank(),
panel.grid.minor=element_blank(),panel.background=element_rect(fill = "white"))

volc+geom_text_repel(data=N_genes, aes(label = Gene), size = 5,
box.padding = unit(0.5, "lines"),
point.padding = unit(0.15, "lines"),segment.size = 0.5, direction = c("both") )
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###########Transcript per million (TPM) normalization
tpm <- function(coun,leng) {
x <- coun/leng
return(t(t(x)*1e6/colSums(x)))
}
N_TPM = tpm(NAc_data1, Nlen)
head(N_TPM)

########### Heatmap
install.packages("pheatmap")
library("pheatmap")

#For All Genes
N_TPM = as.data.frame(N_TPM)
head(N_TPM)
N_TPMmeans = rowMeans(N_TPM)
head(N_TPMmeans)
N_TPMsd<- vector(length=nrow(N_TPM), mode="numeric")
for(i in 1:nrow(N_TPM)){N_TPMsd[i]<-sd(N_TPM[i,])}
head(N_TPMsd)
N_TPMZscore<- (N_TPM-N_TPMmeans)/N_TPMsd
head(N_TPMZscore)
N_TPMZscore = na.omit(N_TPMZscore)
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N_TPMpheat<-as.matrix(N_TPMZscore)

N_annot = data.frame(Sample = factor(rep(c("Sal","Nic","48hWD"),c(4,3,3))))
N_ann = list(Sample = c(Sal="grey80",Nic="grey50","48hWD" ="darkgreen"))
rownames(N_annot) = colnames(N_TPMpheat)
pheatmap(N_TPMpheat, cluster_cols = FALSE,gaps_col = c(4,7),labels_col =
c("","","","","","","","","",""),color = colorRampPalette(c("navy","white","firebrick3"
))(50),annotation_col = N_annot, annotation_colors = N_ann)

# Extracting DEGs (that passed the cutoff) from the matrix
N_TPM1 = NAc_data1[rownames(NAc_data1)%in%NAc48hWD_cutoff$Gene,]
Nlen1 = NAc[NAc$Geneid %in% NAc48hWD_cutoff$Gene,]
Nlen1 = Nlen1$Length
N_TPM1 = tpm(N_TPM1,Nlen1)
head(N_TPM1)
N_TPM2 = as.data.frame(N_TPM1)
head(N_TPM2)
N2_TPMmeans = rowMeans(N_TPM2)
head(N2_TPMmeans)
N2_TPMsd<- vector(length=nrow(N_TPM2), mode="numeric")
for(i in 1:nrow(N_TPM2)){N2_TPMsd[i]<-sd(N_TPM2[i,])}
head(N2_TPMsd)
N2_TPMZscore<- (N_TPM2-N2_TPMmeans)/N2_TPMsd
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head(N2_TPMZscore)
N_pheat<-as.matrix(N2_TPMZscore)

N_annot = data.frame( Sample = factor(rep(c("Sal","Nic","48hWD"),c(4,3,3))))
N_ann = list(Sample = c(Sal="grey80",Nic="grey50","48hWD" ="darkgreen"))
rownames(N_annot) = colnames(N_pheat)
pheatmap(N_pheat,cluster_cols=FALSE,gaps_col=c(4,7),cutree_rows=2,labels_
col=c("","","","","","","","","",""),color=colorRampPalette(c("navy","white","firebrick3"
))(50),annotation_col = N_annot, annotation_colors = N_ann)

##########Two-way Analysis
#Extracting the dataframe of sample treatments to be compared from the
dataframe containing all samples
NAc_SN = NAc_data1[,-(8:10)]
head(NAc_SN)
NAc_SWD = NAc_data1[,-(5:7)]
head(NAc_SWD)
NAc_NWD = NAc_data1[,-(1:4)]
head(NAc_NWD)
SN_col = NAc_col[-(8:10),]
head(SN_col)
SWD_col = NAc_col[-(5:7),]
head(SWD_col)
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NWD_col = NAc_col[-(1:4),]
head(NWD_col)

####### Sal vs Nic
SN_dds = DESeqDataSetFromMatrix(NAc_SN,SN_col,~Treatment)
SN_dds1<-DESeq(SN_dds)
res_SN<-results(SN_dds1)
head(res_SN)

plotMA(res_SN, main="MA Plot with DESeq2: 48hWD Nicotine Studies")
tsig_SN = table(res_SN[,6]<0.2)
tsig_res_SN = which(res_SN[,6]<0.2)
sig_SN = res_SN[tsig_res_SN,]
head(sig_SN)

sig_ordSN = sig_SN[order(sig_SN$log2FoldChange,decreasing = TRUE),]
head(sig_ordSN)
SN_DEG=data.frame(Gene=rownames(sig_ordSN),log2FC=sig_ordSN$log2Fold
Change,pvalue=sig_ordSN$pvalue,padj=sig_ordSN$padj)
row.names(SN_DEG)<- NULL
write.csv(SN_DEG,"Sal_Nic_DEG(48hWD).csv", row.names = FALSE)
SN48hWD_cutoff = SN_DEG[SN_DEG$log2FC>0.5|SN_DEG$log2FC < -0.5,]
write.csv(SN48hWD_cutoff,"Sal_Nic(48hWD)cutoff.csv", row.names = FALSE)
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####### Sal vs 24hWD
SWD_dds = DESeqDataSetFromMatrix(NAc_SWD,SWD_col,~Treatment)
SWD_dds1<-DESeq(SWD_dds)
res_SWD<-results(SWD_dds1)
head(res_SWD)

plotMA(res_SWD, main="MA Plot with DESeq2: 48hWD Nicotine Studies")
tsig_SWD = table(res_SWD[,6]<0.2)
tsig_res_SWD = which(res_SWD[,6]<0.2)
sig_SWD = res_SWD[tsig_res_SWD,]
head(sig_SWD)

sig_ordSWD = sig_SWD[order(sig_SWD$log2FoldChange,decreasing = TRUE),]
head(sig_ordSWD)
SWD_DEG=data.frame(Gene=rownames(sig_ordSWD),log2FC=sig_ordSWD$lo
g2FoldChange,pvalue=sig_ordSWD$pvalue,padj=sig_ordSWD$padj)
row.names(SWD_DEG)<- NULL
write.csv(SWD_DEG,"Sal_WD_DEG(48hWD).csv", row.names = FALSE)
SWD48hWD_cutoff = SWD_DEG[SWD_DEG$log2FC>0.5|SWD_DEG$log2FC <
-0.5,]
write.csv(SWD48hWD_cutoff,"Sal_WD(48hWD)cutoff.csv", row.names = FALSE)
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####### Nic vs 24hWD
NWD_dds = DESeqDataSetFromMatrix(NAc_NWD,NWD_col,~Treatment)
NWD_dds1<-DESeq(NWD_dds)
res_NWD<-results(NWD_dds1)
head(res_NWD)

plotMA(res_NWD, main="MA Plot with DESeq2: 48hWD Nicotine Studies")
tsig_NWD = table(res_NWD[,6]<0.2)
tsig_res_NWD = which(res_NWD[,6]<0.2)
sig_NWD = res_NWD[tsig_res_NWD,]
head(sig_NWD)

sig_ordNWD = sig_NWD[order(sig_NWD$log2FoldChange,decreasing = TRUE),]
head(sig_ordNWD)
NWD_DEG=data.frame(Gene=rownames(sig_ordNWD),log2FC=sig_ordNWD$lo
g2FoldChange,pvalue=sig_ordNWD$pvalue,padj=sig_ordNWD$padj)
row.names(NWD_DEG)<- NULL
write.csv(NWD_DEG,"Nic_WD_DEG(48hWD).csv", row.names = FALSE)
NWD48hWD_cutoff = NWD_DEG[NWD_DEG$log2FC>0.5|NWD_DEG$log2FC <
-0.5,]
write.csv(NWD48hWD_cutoff,"Nic_WD(48hWD)cutoff.csv", row.names = FALSE)
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################################################################
# Determining overlapping genes between experiments. The output was used for
the construction of Venn Diagram.
SN24hWD = No DEGs at the cutoff
SWD24hWD = read.csv("Sal_WD(24hWD)cutoff.csv", header = T)
NWD24hWD = read.csv("Nic_WD(24hWD)cutoff.csv", header = T)
SN48hWD = read.csv("Sal_Nic(48hWD)cutoff.csv", header = T)
SWD48hWD = read.csv("Sal_WD(48hWD)cutoff.csv", header = T)
NWD48hWD = read.csv("Nic_WD(48hWD)cutoff.csv", header = T)
SN_Mic = read.csv("Microglia_SN DEGs (Untrimmed).csv", header = T)
SWD_Mic = read.csv("Microglia_SWD DEGs (Untrimmed).csv", header = T)
NWD_Mic = read.csv("Microglia_NWD DEGs (Untrimmed).csv", header = T)
SN_Ast = No DEGs at the cutoff
SWD_Ast = read.csv("Astrocytes_SWD DEGs (Untrimmed).csv", header = T)
NWD_Ast = read.csv("Astrocytes_NWD DEGs (Untrimmed).csv", header = T)

######## SAL vs NIC
# Two-way Sal/Nic in NAc48hWD experiment vs Microglia48hWD experiment
SN_Mic_48hWD_tab = table(SN48hWD$Gene %in% SN_Mic$X)
SN_Mic_48hWD_overlap

=

SN48hWD$Gene[which(SN48hWD$Gene

SN_Mic$X)]
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%in%

######## SAL vs WD
# Two-way Sal/WD in NAc24hWD experiment vs NAc48hWD experiment
SWD_24h_48hWD_tab = table(SWD24hWD$Gene %in% SWD48hWD$Gene)
SWD_24h_48hWD_overlap

=

SWD24hWD$Gene[which(SWD24hWD$Gene

%in% SWD48hWD$Gene)]

# Two-way Sal/WD in NAc24hWD experiment vs Astrocytes48hWD experiment
SWD_Ast_24hWD_tab = table(SWD24hWD$Gene %in% SWD_Ast$X)
SWD_Ast_24hWD_overlap

=

SWD24hWD$Gene[which(SWD24hWD$Gene

%in% SWD_Ast$X)]

# Two-way Sal/WD in NAc24hWD experiment vs Microglia48hWD experiment
SWD_Mic_24hWD_tab = table(SWD24hWD$Gene %in% SWD_Mic$X)
SWD_Mic_24hWD_overlap

=

SWD24hWD$Gene[which(SWD24hWD$Gene

%in% SWD_Mic$X)]

# Two-way Sal/WD in NAc48hWD experiment vs Astrocytes48hWD experiment
SWD_Ast_48hWD_tab = table(SWD48hWD$Gene %in% SWD_Ast$X)
SWD_Ast_48hWD_overlap

=

SWD48hWD$Gene[which(SWD48hWD$Gene

%in% SWD_Ast$X)]

# Two-way Sal/WD in NAc48hWD experiment vs Microglia48hWD experiment
SWD_Mic_48hWD_tab = table(SWD48hWD$Gene %in% SWD_Mic$X)
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SWD_Mic_48hWD_overlap

=

SWD48hWD$Gene[which(SWD48hWD$Gene

%in% SWD_Mic$X)]
# Two-way Sal/WD in Astrocytes48hWD experiment vs Microglia48hWD
experiment
SWD_Mic_Ast_tab = table(SWD_Ast$X %in% SWD_Mic$X)
SWD_Mic_Ast_overlap = SWD_Ast$X[which(SWD_Ast$X %in% SWD_Mic$X)]

######## NIC vs WD
# Two-way Nic/WD in NAc24hWD experiment vs NAc48hWD experiment
NWD_24h_48hWD_tab = table(NWD24hWD$Gene %in% NWD48hWD$Gene)
NWD_24h_48hWD_overlap

=

NWD24hWD$Gene[which(NWD24hWD$Gene

%in% NWD48hWD$Gene)]

# Two-way Nic/WD in NAc24hWD experiment vs Astrocytes48hWD experiment
NWD_Ast_24hWD_tab = table(NWD24hWD$Gene %in% NWD_Ast$X)
NWD_Ast_24hWD_overlap

=

NWD24hWD$Gene[which(NWD24hWD$Gene

%in% NWD_Ast$X)]

# Two-way Nic/WD in NAc24hWD experiment vs Microglia48hWD experiment
NWD_Mic_24hWD_tab = table(NWD24hWD$Gene %in% NWD_Mic$X)
NWD_Mic_24hWD_overlap

=

NWD24hWD$Gene[which(NWD24hWD$Gene

%in% NWD_Mic$X)]
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# Two-way Nic/WD in NAc48hWD experiment vs Astrocytes48hWD experiment
NWD_Ast_48hWD_tab = table(NWD48hWD$Gene %in% NWD_Ast$X)
NWD_Ast_48hWD_overlap

=

NWD48hWD$Gene[which(NWD48hWD$Gene

%in% NWD_Ast$X)]

# Two-way Nic/WD in NAc48hWD experiment vs Microglia48hWD experiment
NWD_Mic_48hWD_tab = table(NWD48hWD$Gene %in% NWD_Mic$X)
NWD_Mic_48hWD_overlap

=

NWD48hWD$Gene[which(NWD48hWD$Gene

%in% NWD_Mic$X)]

# Two-way Nic/WD in Astrocytes48hWD experiment vs Microglia48hWD
experiment
NWD_Mic_Ast_tab = table(NWD_Ast$X %in% NWD_Mic$X)
NWD_Mic_Ast_overlap = NWD_Ast$X[which(NWD_Ast$X %in% SWD_Mic$X)]

################################################################
# Correlation analysis between samples
install.packages("corrplot")
library("corrplot")
col4 <- colorRampPalette(c("#053061","#053061","#053061","white","darkred"))

#For the withdrawal group from 24hWD and 48hWD experiments
twentyfour = dataframe of withdrawal group from 24hWD experiment
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fortyeight = dataframe of withdrawal group from 24hWD experiment
vec = unique(rbind(twentyfour, fortyeight))
WD_cor = cor(vec[,c(8:10,18:20)], method = "spearman")
WD_cor1 = ((WD_cor) + 1)/2
head(WD_cor1)
corrplot(WD_cor1,method="shade",cl.lim=c(0,1),col=col4(20),cl.cex=1.3,addgrid.
col = "grey")

#For the cell type-specific (astrocytes and microglia) experiment
cell = dataframe of astrocytes and microglia samples combined
cell_cor = cor(cell, method = "spearman")
cell_co = ((cell_cor) + 1)/2
head(cell_co)

#Without clustering option
corrplot(cell_co,method="shade",cl.lim=c(0,1),col=col4(20),cl.cex=1.3,addgrid.col
= "grey")
#With hierarchical clustering option
corrplot(cell_co,method="shade",cl.lim=c(0,1),col=col4(20),cl.cex=1.3,addgrid.col
= "grey",order = "hclust", hclust.method = "median")
#Removing outliers and re-plotting
cell_cor1 = cell_co[-c(5,10),-c(5,10)]
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corrplot(cell_cor1, method = "shade", cl.lim = c(0,1), col = col4(20) ,cl.cex =
1.3,addgrid.col = "grey")

################################################################
# Validation of cell types using RNA seq expression data of classic cell markers
gene=c("Tmem119","P2ry12","Itgam","Csf1r","Cx3cr1","Gfap","S100B","Aldh1l1",
"Slc1a3")

cellTPMZscore1 = Z-score dataframe for astrocytes and microglia samples
cell2 = cellTPMZscore1[rownames(cellTPMZscore1) %in% gene,]
head(cell2)
cell2a = cell2[,-c(5,10)]
cell3 = as.matrix(cell2a)
cell_annot = data.frame(Sample = factor(rep(c("Microglia","Astrocytes"),c(8,8))))
cell_ann = list(Sample = c(Microglia ="darkgreen", Astrocytes ="grey10"))
rownames(cell_annot) = colnames(cell3)
pheatmap(cell3,cluster_cols=FALSE,gaps_col=c(8),color=colorRampPalette(c("d
arkblue","white","brown"))(50),annotation_col = cell_annot, annotation_colors =
cell_ann)
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